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Abstract
I studied the capabilities of the two DNA lesions 8-oxo-guanine and cisplatin intrastrand
crosslinked 1,2-d(GpG) or Pt-GG to cause mutations in mammalian cells. Using isogenic cell
lines generated from mice with selective gene knockouts of distinct DNA polymerases as
models, I deduced the biological functions of the translesion DNA polymerases Pol eta, Pol
kappa, Pol iota, Rev1 and Rev3L on bypassing each of the lesions 8-oxo-G and Pt-GG. My
study takes advantage of the Next Generation Sequencing (NGS) technology to determine
mutagenic effects of the DNA lesions in vivo and effects of translesion DNA polymerases on
bypassing the lesions. Through adapting a translesion synthesis (TLS) assay into a highthroughput TLS assay which uses NGS, I eliminated steps in the traditional TLS assay that
involves E. coli. My study reveals that 8-oxo-guanine caused a high frequency of C->A
substitutions, and that significantly, Pol eta correctly bypassed 8-oxo-G in cells. The high
mutation rate of 8-oxo-G underlines the importance of DNA repair to remove this lesion
before it is replicated. By contrast, Pt-GG caused very few mutations in vivo: the mutation
rate of Pt-GG was only two times the background error rate in my experiment. The five
translesion DNA polymerases studied bypassed Pt-GG in an error-prone manner;
specifically, Rev3L and Rev1 DNA polymerases can each bypass the lesion and Pol iota
might share the function of Pol kappa or enhance that of Pol eta to bypass the lesion. Since
Pt-GG does not appear to block DNA replication more than 8-oxo-G in mammalian cells, the
cytotoxicity of the drug cisplatin that produces the cisplatin-DNA adduct is likely attributed
to other causes, such as inter-strand cisplatin-DNA adducts that are more potent for stalling
DNA replication.
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Chapter 1
1

Introduction

1.1

Y-family DNA polymerases are prone to making mutations

Information encoded by genomic DNA is not static. The biological content of the genome
adapts to the environment and is shaped by outside forces over time. One way genomic
DNA sequences are changed is from chemical modifications of nucleotides. Y-family
DNA polymerases bypass modified nucleotides or DNA lesions in a process called
translesion synthesis (TLS) (Yang and Woodgate, 2007; Sale et al., 2012). Compared to
DNA polymerases that accurately copy the whole genome, Y-family polymerases are
prone to making mutations (Ohmori et al., 2001).
Mutation is a natural phenomenon and a driving force of evolution. One way that
mutations can arise is when DNA polymerases bypass lesions that block normal DNA
replication. A stalled replication fork if not rescued by translesion DNA polymerases
would fall apart—proteins of the replication machinery disassemble and a double
stranded break forms. It is generally accepted that Y-family polymerases maintain
genome stability by allowing DNA replication to continue despite DNA lesions that are
ubiquitously present. This way, translesion synthesis ensures the cell’s survival and
tolerates DNA damage; on the other hand, it increases the likelihood that the base
inserted opposite to the DNA lesion would be changed.
Translesion synthesis is one of the ways whereby DNA mutations occur. It's a major
source of point mutation that involves change in the nucleotide opposite to the DNA
lesion. Spontaneous mutations without facilitation of DNA lesions are rare but can arise
in cells. At the gene level, these mutations are base substitution, insertion and deletion of
one or several nucleotides given rise to by replication errors and spontaneous loss of
DNA bases. There are also copy number DNA mutations such as expansion of
trinucleotide DNA repeats exemplified in a genetic disease called fragile X syndrome,
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whereby thousands of nucleotides were duplicated from CGG repeats. DNA mutations
that affect production and folding of proteins are deleterious and could lead to increased
susceptibility to illness and disease.

Figure 1. Possible outcomes for when DNA replication is stalled by a DNA lesion in
the template
When DNA replication is stalled by a DNA lesion (indicated by the red circle), the cell
can use the damage tolerance pathway to bypass the lesion (case 1). This involves two
polymerase-switching events whereby in the first event, a replicative DNA polymerase is
replaced by a translesion DNA polymerase which inserts a nucleotide across from the
lesion, and in the second event, the replicative DNA polymerase is recruited back to
continue normal DNA replication. Alternatively, the DNA replication machinery can skip
the DNA lesion in what is called the damage avoidance pathway (cases 2 and 3) whereby
the replicative DNA polymerase reinitiates DNA replication downstream from the lesion,
leaving a small single stranded gap (Jansen, 2006). This gap is filled by translesion DNA
polymerases later in the S or G2 phase of cell cycle (Daigaku et al., 2010; Karras and
Jentsch, 2010; Elvers et al., 2011), and the nucleotide incorporated opposite to the lesion
could either form the correct or mismatched base pair with the lesion (case 2). The single
stranded gap can also be repaired by homologous recombination mediated by template
switching (case 3). In this scenario, the DNA segment containing the lesion is not used as
a template for DNA replication, thus the mutagenic effect of the DNA lesion is
completely avoided. Failing the damage tolerance and the damage avoidance measures, a
stalled DNA replication fork can be nicked by a single stranded endonuclease to form a
double stranded break (case 4) whereupon DNA replication is terminated.
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Translesion synthesis is a major source of point mutations or variations in the genome.
These variations—if they are not strongly deleterious, are passed on for as long as a cell’s
lineage is kept alive, without causing harmful effects to daughter cells. The purpose of
studying translesion synthesis is to look at the initial conditions that perturb the genome.
Similar to the butterfly effect (Lorenz, 1963; Lorenz, E.N., 1972), small and random
changes that are regarded as errors or noises in the genome can have a remarkable effect
on determining the cell’s fate. There is an element of chance and randomness in what
shapes and what continues to shape the human genome. While the rate of mutation is
tightly controlled in normal cells, a high rate of mutation is characteristic of tumor cells
(Jackson and Loeb, 1998). Accumulation of point mutations increases the risk of
developing cancer, especially if it is accompanied by defects in the cell’s DNA repair and
cell cycle control mechanisms (Hartwell and Kastan, 1994; Lodish et al., 2000).
Understanding the regulation of non-stringent DNA polymerases, such as those of the Yfamily, and how their regulations intercept DNA repair and cell cycle control pathways,
are key to understanding the role of translesion synthesis in the formation of cancer
(Lange et al., 2011; Makridakis and Reichardt, 2012).
While translesion synthesis works toward subtly changing the sequence of genomic
DNA, not all mutations are detrimental and sometimes new functions are created, such as
in generating antibody diversity. Somatic hypermutation in activated B cells is an active
mutagenic process carried out by Y-family DNA polymerases on normal DNA templates
(Faili et al., 2002; Delbos et al., 2005). The DNA polymerases produce mutations in the
variable regions of immunoglobulin genes (VH/VL), thus giving rise to antibodies
recognizing different antigens (McDonald et al., 2003; Delbos et al., 2005; Martomo et
al., 2005; Faili et al., 2002).
The behaviors of Y-family DNA polymerases have been studied in the contexts of
disease and of adaptive immunity. One way to elucidate the functions of Y-family DNA
polymerases is to find out the DNA lesions they are adept at bypassing. A good example
of a translesion DNA polymerase that can correctly bypass DNA lesions and thus
contribute to reducing the incidence of a disease is the human Pol eta.
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1.2

A brief history of the study of Y-family DNA polymerases

The human Pol eta gene (POLH or XPV) is defective in some patients with an inherited
skin disorder called Xeroderma Pigmentosum-Variant (XP-V). Patients with this disease
are predisposed to sunlight induced skin cancer and their skins retain high levels of
damage due to DNA lesions, such as cis-syn thymine-thymine dimers arising from UV
irradiation. Cells of these patients have normal nucleotide excision repair to remove these
DNA lesions, but lack specialized DNA polymerases to bypass the lesions in DNA
replication.
The XPV protein first isolated in HeLa cells is the human Pol eta (Masutani et al., 1999),
its amino acid sequence shares 20% identity with the Saccharomyces cerevisiae RAD30
protein that encodes the yeast Pol eta (Johnson et al., 1999). Cell extracts of XP-V
patients cannot bypass thymine dimers, however, when purified recombinant XPV
proteins were added there was bypass activity. It was established from this experiment
that the human Pol eta is able to bypass thymine-thymine dimers in cells and that a defect
in the POLH gene causes skin disease.
According to their phylogenetic relationships to yeast RAD30, POLH along with three
other human DNA polymerase genes (POLK, POLI and REV1) belong to the Y-family
(Burgers et al., 2001; Ohmori et al., 2001). Over 200 orthologs of Y-family DNA
polymerase genes have been identified in all three kingdoms of life (Yeiser et al., 2002).
We would not have learned about those in higher eukaryotes without first identifying
their homologous genes in yeast and in bacteria—for example, yeast RAD30 was
discovered by its homology to DinB and UmuC genes in Escherichia coli that encode
DNA Polymerases IV and V, respectively (McDonald et al., 1997). The study of
translesion synthesis began in the 1970s (Radman et al., 1974), and using E. coli, a twopolymerase model was developed to describe translesion synthesis as a process that
occurs in two steps—insertion and extension, each effected by a different error-prone
DNA polymerase (Radman et al., 1974). The two-polymerase model is also widely
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adopted as the mechanism of translesion synthesis in higher eukaryotes (Friedberg et al.,
2005; Shachar et al., 2009).
The two-polymerase model gained support partly because of the regulation of Y-family
DNA polymerases by a ring-structured protein called Proliferating Cell Nuclear Antigen
(PCNA) which functions as a sliding clamp at DNA replication fork (Tsurimoto, 1999;
Maga and Hübscher, 2003; Naryzhny, 2008). Human PCNA is a homotrimer for which
each of its subunits can bind to a Y-family DNA polymerase (Kannouche et al., 2004;
Bienko et al., 2005; Haracska et al., 2005; Guo et al., 2006; Jansen et al., 2007).
Recruitment of more than one Y-family DNA polymerases by PCNA favored the twopolymerase model.
The model also gained support with the evidence that Y-family DNA polymerases colocalize to replication foci in the nuclei when cells are induced by DNA damage. This
suggests that the bypass of DNA lesions can be coordinated among the DNA
polymerases (Kannouche et al., 2003). Furthermore, mutations are observed not only
opposite to but also adjacent to DNA lesions in cellular studies done using a translesion
synthesis assay (Avkin and Livneh, 2002; Shachar et al., 2009; Taggart et al., 2013) and
these mutations are believed to be made by different error-prone DNA polymerases. In
my work, I will call into question the two-polymerase model and argue that mutations
adjacent to DNA lesions do not result immediately from translesion synthesis.

1.3

Common features of Y-family DNA polymerases

The overall structure of a Y-family DNA polymerase resembles a ‘right-hand’ with palm,
finger and thumb domains that form the protein’s active site (Friedberg et al., 2001). In
addition, a Y-family DNA polymerase has a domain called the ‘Little Finger’ (Ling et al.,
2001); its amino acid sequence is divergent among Y-family members (Boudsocq et al.,
2004). Tethered to the thumb domain, the ‘Little Finger’ domain binds DNA. It was
thought that movement of the ‘Little Finger’ domain modulates substrate specificity of Yfamily DNA polymerases, so that each of them is unique in the type of DNA lesions it
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can bypass (Boudsocq et al., 2004). However, my results show that there are functional
overlaps among Y-family DNA polymerases in the cell to bypass DNA lesions.
Y-family DNA polymerases are tolerant of unusual local structures in DNA caused by a
damaged nucleotide. A major reason is because their active sites have a larger space than
replicative DNA polymerases, so they can accommodate a base pair mismatch,
Hoogsteen base pairing or a base flip-out in DNA template caused by a DNA lesion
(Friedberg et al., 2001). This is not to say that Y-family DNA polymerases do not select
for incoming nucleotides, but rather, they tend to make flexible choices. Another reason
that Y-family DNA polymerases can replicate through DNA lesions is that they lack a 3’5’ exonuclease or proofreading activity (Friedberg et al., 2001). While this ensures the
complete bypass of a DNA lesion in that the enzyme does not track backwards to remove
a nucleotide it has just inserted, the lack of proofreading activity makes the DNA
polymerases error-prone. The error frequency of a Y-family DNA polymerase on normal
DNA template is one mistake in every 102 to 104 nucleotides replicated (Ollivierre et al.,
2011; Tissier et al., 2000) compared to one mistake in every 106 to 108 nucleotides
synthesized by a replicative DNA polymerase that has intrinsic proofreading activity
(Kunkel, 2004). Unlike replicative DNA polymerases that can incorporate thousands of
nucleotides in a stretch, Y-family DNA polymerases disengage from the template after
adding several nucleotides (Ohashi et al., 2000; Friedberg et al., 2001; Boudsocq et al.,
2004). Y-family DNA polymerases are also slower than replicative DNA polymerases in
catalyzing polymerization reactions (Beard et al., 2002).

1.4

Distinct functions of translesion DNA polymerases

Each Y-family DNA polymerase was thought to have unique structural properties that
enable it to bypass different DNA lesions, but Rev1 is an exception because it was first
discovered as a protein that has nucleotidyl transferase activity in S. cerevisiae and it
preferentially inserts dCMP opposite abasic site (Nelson et al., 1996). There are at least
two ways Rev1 can function in translesion synthesis depending on whether its catalytic
domain is involved.
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First, it was recently shown that Rev1 can bypass a DNA lesion directly, the Rev1 dCMP
transferase domain is required to bypass 1,N6-ethenoadenine (Zhou et al., 2010). Second,
Rev1 can mediate translesion synthesis indirectly by acting as a scaffold, which does not
require the protein’s catalytic domain to recruit other DNA polymerases, such as Pol
kappa, Pol eta, Pol iota and Pol zeta (Guo et al., 2003; Ohashi et al., 2004; Tissier et al.,
2004).
Pol zeta is a B-family DNA polymerase that plays an important role in error-prone
translesion synthesis (Gan et al., 2008). The Rev3L protein and the Rev7 protein are the
catalytic subunit and the accessory subunit of Pol zeta, respectively. The REV3L gene is
essential for mouse embryonic development (Wittschieben et al., 2006). Cells with
targeted disruption of REV3L have reduced numbers of point mutations and are very
sensitive to UV light and some DNA damaging agents (Gan et al., 2008; Wittschieben et
al., 2006). Therefore, Rev3L is essential for bypassing various types of DNA lesions and
in error-prone translesion synthesis (Jansen et al., 2009). It has been reported that Rev3
adopts the function of an extender DNA polymerase, acting sequentially after an insertor
DNA polymerase to extend from a lesion site (Acharya et al., 2006; Lee et al., 2014).
Rev1 and Rev3L cooperate in translesion synthesis through an interaction mediated by
Rev7 (Murakumo et al., 2001; Kikuchi et al., 2012). Rev1 and Rev3 also contribute to the
process of homologous recombination to repair double strand breaks induced in cells by
ionizing radiation (Sharma et al., 2011; Wittschieben et al., 2010) and post-replication
gaps resulting from DNA lesions (Jansen et al., 2009). Regulations of Rev1 and Rev3 are
governed by PCNA and the consequences of Rev1 and Rev3’s interactions are dependent
on the states of post-translational modifications of PCNA (Hoege et al., 2002; Stelter and
Ulrich, 2003; Andersen et al., 2008). Mono-ubiquitinlation of PCNA controls the timing
of translesion synthesis and regulates the access of the Rev3L protein and Y-family DNA
polymerases to DNA templates (Vidal et al., 2004; Kannouche et al., 2004; Garg et al.,
2005; Bi et al., 2006; Guo et al., 2006; Chun and Jin, 2010).
Pol iota is considered the most error prone among the four human Y-family DNA
polymerases (Tissier et al., 2000; Zhang et al., 2000a; Makarova and Kulbachinskiy,
2012) because it has not yet been shown what kind of DNA lesions Pol iota can bypass
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correctly. The pol iota gene, arising from an ancestral gene duplication of Pol eta, is not
essential for survival. Mice with homozygous knockout of the Pol iota gene (POLI) have
normal phenotypes (McDonald et al., 2003).
On the other hand, mice with a knockout of the Pol eta gene (POLH) are susceptible to
developing skin tumors after UV irradiation (Lin et al., 2006). Thus, Pol eta protects
mammalian cells from DNA damage caused by UV light.
Pol kappa can replicate past several bulky DNA adducts in vitro, including
benzo(a)pyrene (Zhang et al., 2000b; Ogi et al., 2002; Ogi and Lehmann, 2006). Mouse
and chicken cells with complete disruption of the POLK gene grow normally but show
slightly increased UV sensitivity (Ogi et al., 2002; Okada et al., 2002). Pol kappa on its
own cannot bypass major UV lesions such as cis-syn T-T dimers in vitro, but it is able to
extend from a nucleotide inserted to the 3’T of the dimer by another DNA polymerase
(Carpio et al., 2011; Zhang et al., 2000b). Pol kappa has been shown to act as an extender
DNA polymerase in translesion synthesis as well as having a role in nucleotide excision
repair (NER) (Ogi and Lehmann, 2006).

1.5

Project

The initial aim of my project is to investigate the cellular function of Pol iota on
bypassing the DNA lesion 8-oxo-guanine. X-ray crystal structures of Pol iota solved by
former members in the Ling Lab have shown that the DNA polymerase can bypass 8oxo-G accurately in vitro (Kirouac and Ling, 2011a). Therefore, by extension, I
hypothesized that Pol iota can accurately bypass 8-oxo-G in vivo. If this function of Pol
iota could be confirmed in the cell and that no other Y-family DNA polymerases shared
the same function, Pol iota would have the indispensable role of protecting cells from
oxidative stress that produces 8-oxo-G.
My project expanded to include the study of another DNA lesion, the cisplatin
instrastrand crosslinked 1,2-d(GpG) or Pt-GG for short. I obtained isogenic mouse
embryonic fibroblast (MEF) cell lines that allowed me to study translesion synthesis of
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each of the 8-oxo-G and the Pt-GG lesion by all four of the human Y-family DNA
polymerases (Pol iota, Pol kappa, Pol eta, Rev1) and Rev3L. 8-oxo-G and Pt-GG would
make for valuable comparisons because I assumed, as were implicated in literatures, that
8-oxo-G, a relatively small DNA lesion does not block DNA replication, and that Pt-GG,
a purine dimer does. In this project, I found that Pt-GG and 8-oxo-G had similar blocking
effects to DNA replication in mammalian cells.
From the perspective of generating mutations, interactions between DNA lesions and
translesion DNA polymerases contribute to shaping the mutational landscape of the cell.
My work has added knowledge to the mutagenicity of the two DNA lesions 8-oxo-G and
Pt-GG and to the biological functions of translesion DNA polymerases on bypassing
these two lesions.

1.6

8-oxo-guanine

8-oxo-guanine (8-oxo-G) is a very common DNA lesion formed by the chemical reaction
between a guanine base and reactive oxygen species (Figure 2).

Figure 2 How 8-oxo-guanine is formed.
Reactive oxygen species such as superoxide radical (O2·-), hydrogen peroxide (H2O2) and
hydroxyl radical (·OH) are generated in the body as byproducts of oxygen metabolism
and are found in the environment. Guanine is the base most prone to DNA oxidation
(Weimann et al., 2002). The steady state concentration of 8-oxo-G in cells remains in
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debate because there is no reliable method to accurately measure its concentration
(Marnett, 2000). The level of 8-oxo-G in human tissues has been reported by several labs
and the numbers differ widely, ranging from one adduct in 103 nucleotides to one adduct
in 107 nucleotides (Cadet et al., 1997). While the abundance of 8-oxo-G in genomic DNA
remains controversial (Marnett, 2000), it is generally considered pretty high (Bohr et al.,
2002; van Loon et al., 2010). Free 8-oxo-G in the cellular nucleotide pool can be
incorporated into DNA (Satou et al., 2009) and deoxyguanosine in DNA can be directly
converted to 8-oxo-G. The DNA lesion is removed by DNA glycosylase OGG1 in base
excision repair pathway (Boiteux and Radicella, 2000; Hazra et al., 2001), and that which
is not removed causes a high frequency of C->A transversion mutation when replicated
(Cheng et al., 1992). My study shows that the mutation frequency of 8-oxo-G in
mammalian cells is very high, in fact higher than all previously reported, and the cell
lines used should have normal OGG1 genes. This finding underlines the importance of
DNA repairs, perhaps in addition to the action of DNA glycosylase OGG1, to remove 8oxo-G before its replication.

1.7

Repair of 8-oxo-G lesions by base excision repair

Base excision repair is the predominant pathway for removing 8-oxo-G and other DNA
damages caused by free radicals and reactive species generated by metabolism (Clancy,
2008). In mammalian cells, 8-oxoguanine-DNA glycosylase (OGG1) and endonuclease
III homolog 1 (NTH1) are two enzymes that recognize and cleave oxidized guanine bases
from DNA (Hailer et al., 2005). First, DNA glycosylase releases a damaged base and thus
creates an abasic site by cleaving a covalent bond called the N-glycosidic bond between
the DNA base and ribose sugar. Then, apurinic/apyrimidinic (AP) endonucleases cleaves
the phosphodiester bond in DNA at the abasic site and makes a single stranded break.
The break is repaired by either DNA synthesis with strand displacement (long-patch
pathway) or by another pathway (called short patch) that removes the 5’ deoxyribose
phosphate group at the abasic site by enzymes with 5’ deoxyribose phosphatase lyase
activity followed by DNA synthesis. The final step of both pathways is sealing of the
single stranded gap by DNA ligase. OGG1 knockout mice accumulate more 8-oxo-G
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lesions in hepatocytes but not in splenocytes, spermatocytes and kidney cells (Minowa et
al., 2000; Osterod et al., 2001). OGG1-deficient fibroblast culture does not accumulate
more 8-oxo-G lesions than the control wild type fibroblast culture. NTH1 knockout mice
are healthy (Ocampo et al., 2002). Both OGG1-deficient mice and NTH1-deficient mice
do not have association with increased incidence of cancer, suggesting that there are other
base excision repair enzymes in mammalian cells that recognize and remove 8-oxo-G
lesions (Dou et al., 2003; Hailer et al., 2005). MUYTH is a DNA glycosylase in human
that excises an adenine base mispaired with 8-oxo-G. Mutations in the MUTYH gene are
associated with heritable predisposition to colorectal cancer.

1.8

Cisplatin intrastrand crosslinked 1,2-d(GpG)

Cisplatin is an anti-tumor agent used for treating a variety of cancers. Pt-GG is a major
species (65%) of the various types of interstrand and intrastrand cisplatin-DNA adducts
formed in cancer patients (Fichtinger-Schepman et al., 1987; Jung and Lippard, 2007;
Cepeda et al., 2007). It is believed that cisplatin kills rapidly dividing tumor cells partly
because Pt-GG blocks DNA replication (Vaisman et al., 2000; Chijiwa et al., 2010).

Figure 3 How Pt-GG is formed.
Cisplatin crosslinks the N7 atoms of adjacent guanosine nucleotides within the same
DNA strand to form Pt-GG (image was provided by colleague Chuanbing Bian).

12

Following this rationale, the tumor cell develops resistance to cisplatin when it has
acquired the ability to bypass cisplatin-DNA lesions and particularly, when the bypass of
the lesion inserts the correct nucleotides. Researchers studying translesion synthesis of
Pt-GG saw DNA polymerases with the ability to bypass the lesion as potential drug
targets in chemotherapy. They postulated that drugs inactivating these DNA polymerases
would reduce cisplatin resistance in cancer treatment (Zhao et al., 2012).
In my study, I found that Pt-GG was bypassed correctly 99% of the time in the
mammalian cell due to DNA polymerase(s) other than those of the Y-family and other
than Rev3L. The translesion DNA polymerases bypassed Pt-GG in an error-prone
manner, and these enzymes were responsible for cisplatin resistance to the extent that
they could bypass the DNA lesion. This result implies that the drug mechanism of
cisplatin was likely not due to the direct effect of Pt-GG on blocking DNA replication,
because the lesion was bypassed relatively efficiently and by several DNA polymerases
in the cell. On the other hand, cisplatin also generates interstrand DNA adducts, and it is
conceivable that these DNA lesions would be highly blocking to DNA replication and
may therefore be responsible for the drug’s cytotoxicity.

1.9

Repair of Pt-GG lesions by nucleotide excision repair

Nucleotide excision repair (NER) is the predominant pathway for removing bulky and
dinucleotide DNA lesions, such as cyclobutane-pyrimidine dimers and 6-4 photoproducts
induced by UV radiation. Nucleotide excision repair is also thought to be the major
pathway for removing Pt-GG lesions (Nouspikel, 2009; Wang et al., 2011). In
mammalian cells, there are at least 18 protein complexes involved in nucleotide excision
repair (Clancy, 2008), and defects in some of the proteins are associated with the diseases
Xeroderma Pigmentosum and Cockayne Syndrome (Nouspikel, 2009). In nucleotide
excision repair, distortion in local DNA structure caused by Pt-GG is recognized by
proteins XPA, RPA and the XPC-hHR23B complex, then the two strands of DNA around
the lesion are pried apart by the DNA helicase TFIIH in an ATP-dependent manner. The
strand containing the lesion is cleaved at the 3’ end by XPG nuclease and at the 5’ end by
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the ERCC1-XPF nuclease, thereby releasing a short DNA fragment that is 24-32
nucleotides long (Wood, 1997). Synthesis across the short gap is carried out by the
holoenzymes of DNA polymerase δ or ε, mediated by PCNA and finally, the single
stranded gap is sealed by DNA ligase (Wood, 1997). It was also reported that mismatch
repair could be involved in repairing Pt-GG lesions because the human mismatch repair
protein hMSH2 binds to Pt-GG (Duckett et al., 1996; Mello et al., 1996). The
mechanisms for removing Pt-GG lesions are different from that for removing 8-oxo-G
lesions.

1.10 Translesion synthesis assays
To study mutations arising from DNA lesions in mammalian cells, I used a quantitative
translesion synthesis (TLS) assay (Ziv et al., 2012). To deduce the functions of
translesion DNA polymerases on bypassing the lesions in vivo, I obtained pairs of
isogenic mouse embryonic fibroblast cell lines that were generated from knockout mice,
where the mutant cell lines have specific knockouts of translesion DNA polymerases. I
could infer the biological function of a DNA polymerase by comparing a mutant cell line
to its isogenic wild type cell line. In the TLS assay, double stranded plasmids containing
a small gap with and without a site-specific DNA lesion are co-transfected in equal
amounts into mammalian cells, inside which the plasmids do not replicate but their gaps
are filled. Then the plasmid DNAs are retrieved from the cell by the alkaline lysis
method, which ensures that only the fully double stranded plasmids are retained and any
unfilled or unrepaired gap plasmids are removed. Then I focused on two questions: First,
what are the nucleotides that have been incorporated against the DNA lesions and second,
what is the efficiency at which the lesion gap plasmid is repaired relative to the control
gap plasmid, in other words, what is the efficiency at which the DNA lesion is bypassed
relative to a regular nucleotide. I used two different approaches to address these
questions: the traditional TLS assay and the high-throughput TLS assay. The traditional
TLS assay uses E. coli to amplify the plasmids and Sanger Sequencing to determine the
plasmid sequences (Ziv et al., 2012). The high-throughput TLS assay, which is one of the
innovations in my project, uses PCR to amplify the gap regions of the plasmids and Next
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Generation Sequencing to determine their sequences. The two approaches generated very
different results that would make for an interesting comparison of the immediate effect
versus the long term effect of a DNA lesion in the cell.
One of the advantages of the translesion synthesis assay is that the lesion gap plasmid is
introduced into the cell along with the control gap plasmid that does not have a DNA
lesion. Thus, the blocking effect of a DNA lesion can be measured by comparing the gap
filling efficiency of the lesion plasmid relative to that of the control plasmid.
There are two major assumptions of the translesion synthesis assay. First, a DNA lesion
in the gap plasmid is not removed in the cell prior to gap-filling. Second, a mismatched
base pair resulting from translesion synthesis is preserved and unaltered when the
plasmid is incubated in the mammalian cell. It has been shown that base excision repair is
not active in the seven-hour period following transfection of the gap plasmids into the
mammalian cell (Ziv et al., 2012).
An alternative substrate to use in the TLS assay is a single stranded gap plasmid that
replicates in the mammalian cell (Karata et al., 2009; Pandya and Moriya, 1996; Watt et
al., 2007). Some investigators have argued that this is a better model than the double
stranded gap plasmid model to study translesion synthesis in DNA replication because
the latter simulates gap-filling in DNA repair processes that occur in a different cell cycle
stage. It has been shown, however, that translesion DNA polymerases are active in the
late S and G2 phases of the cell cycle when the double stranded gap plasmid is being
repaired (Daigaku et al., 2010; Karras and Jentsch, 2010; Diamant et al., 2011).
Therefore, the double stranded gap plasmid is an appropriate substrate for studying
mutations produced by translesion DNA polymerases.
The traditional TLS assay has several drawbacks. First, to study the spectrum of
mutations caused by a DNA lesion, the traditional TLS assay uses E. coli to amplify and
separate the control plasmids and lesion plasmids prior to Sanger sequencing. This makes
the results questionable because the DNA sequences can undergo additional changes in
bacteria as bacterial cells divide and multiply. Second, to study the bypass efficiency of a
DNA lesion, the traditional TLS assay takes the ratio of the number of bacterial colonies
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arising on a kanamycin plate, which selects for the lesion plasmids, to that arising on a
chloramphenicol plate, which selects for the control plasmids. Since bacteria have
different growth preferences in culturing media with different antibiotics, this method of
measuring the translesion synthesis efficiency is flawed. Third, the traditional TLS assay
is inefficient, and thus limits the amount of sequence information that can be obtained
from each transfection experiment; any conclusions drawn from a small number of
samples are misleading.
In adapting the traditional TLS assay into a high-throughput TLS assay, I replaced the
steps in the traditional TLS assay that used E. coli with PCR, so instead of amplifying the
whole plasmid in bacteria, a small region on the plasmid was amplified in a test tube. I
designed a multiplexed study of the two DNA lesions 8-oxo-G and Pt-GG, which were
acted upon by each of the five translesion DNA polymerases (Pol iota, Pol kappa, Pol eta,
Rev1 and Rev3). I used barcoded primers in PCR reactions to keep track of DNA
samples of different transfection experiments and pooled all the PCR products together to
do Next Generation Sequencing (NGS). For positive control, I used fully double stranded
plasmids with known sequence in PCR reactions to monitor experimental errors. For
negative control, I incubated gap plasmid mixture with mammalian cells in the absence of
transfection reagent to show that only plasmids that had been repaired in cells and were
double stranded would be preserved (not destroyed by alkaline lysis) and sequenced. A
control that is missing is to use the lesion gap plasmid as template in PCR reaction to
check the effect of recombinant DNA polymerase used in PCR. The high-throughput
TLS assay generated thousands and tens of thousands of sequences for each transfection
experiment, so the NGS technology greatly increased the sample size and the statistical
power of my study. Before implementing the high-throughput TLS assay, however, I
obtained some results using the traditional TLS assay. I will reconcile the difference in
findings of the two methods in the Discussion section.

1.11 Objectives and hypotheses
This thesis can be read with a focus on any of the following three dimensions:
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1)

The mutagenic properties of the two DNA lesions 8-oxo-G and Pt-GG in terms of

their mutation frequency (Section 3.1 & 3.6), mutation spectrum (Section 3.2 & 3.7) and
bypass efficiency (Section 3.12). Comparisons were made between the control plasmids
and the lesion plasmids to elucidate the effect of a DNA lesion. Properties of 8-oxo-G
lesion and Pt-GG lesion were compared in the Discussion (Section 4.3).
2)

The roles of the translesion DNA polymerases Pol iota, Pol eta, Pol kappa, Rev1

and Rev3L on the bypass of either 8-oxo-G (Section 3.4 & 3.5) or Pt-GG (Section 3.83.11). Comparisons were made between a cell line that is wild type for a particular
translesion DNA polymerase gene and its isogenic mutant cell line that is deficient for
that gene to deduce the in vivo functions of the translesion DNA polymerase (Appendix
E).
3)

A comparative and critical analyses of the results obtained from the traditional TLS

assay and those obtained from the high-throughput TLS assay. In the discussion section,
results of the traditional TLS assay and those of the high-throughput TLS assay are
compared (Section 4.1) and reconciled (Section 4.7 to 4.9).
In the early phase of this project, I formulated hypotheses based on the reasoning that if a
DNA polymerase has the ability to bypass a particular DNA lesion correctly in vitro, it
would also have a similar function in vivo. My first hypothesis is that Pol iota can
accurately bypass 8-oxo-G lesions in mammalian cells (Section 3.4). My second
hypothesis is that Pol eta can accurately bypass Pt-GG lesions in mammalian cells
(Section 3.8). Because the POLI gene is phylogenetically related to the POLH gene, Pol
iota and Pol eta might have similar functions; I further hypothesized that Pol iota, in
addition to Pol eta can correctly bypass Pt-GG in cells (Section 3.9). This last hypothesis
sought to complement the work of Chuanbing Bian, my colleague who was working on
determining the kinetics and solving the X-ray crystal structures of Pol iota on bypassing
the Pt-GG lesion. All three of the hypotheses were first investigated by the traditional
TLS assay and later by the high-throughput TLS assay.
The high-throughput TLS assay extended the scope of my project beyond the initial
hypotheses. I used the assay to determine the mutagenic properties of 8-oxo-G and Pt-GG
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and to explore which of the translesion DNA polymerases (Pol iota, Pol eta, Pol kappa,
Rev1 and Rev3) bypassed the DNA lesions in mammalian cells. Data of the highthroughput TLS assay could not be analyzed in the same way that data of the traditional
TLS assay were analyzed. At first, I thought results of the high-throughput TLS assay
would validate those of the traditional TLS assay, but it turned out not to be the case.

1.12 Significance
A change in methodology from the traditional TLS assay to the high-throughput TLS
assay led to new understandings about the properties of the two DNA lesions 8-oxo-G
and Pt-GG and about translesion synthesis in the mammalian cell. My project generated
new hypotheses about the in vivo functions of translesion DNA polymerases, overturned
previous assumptions on the blocking effects of the two DNA lesions, and called into
question the two-polymerase model.
Results of the traditional TLS assay are totally different from those of the highthroughput TLS assay even though they are all produced from the same initial condition,
which is a single DNA lesion in the gap plasmid. The high-throughput TLS assay
captured a still photograph and the traditional TLS assay captured a time-lapsed
photograph of mutations arising from a DNA lesion. The results of the two methods
provided insights into the immediate versus the long-term effect of a DNA lesion, where
the latter had been influenced by the selective pressure of the cell.
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Chapter 2
2

Materials and methods

2.1

Plasmids

Two plasmids, pSKSL-CmR (3618 bp) and pSKSL-KanR (3365 bp), were obtained from
Omer Ziv from Dr. Zvi Livneh’s laboratory (Weizmann Institute of Science). The
sequences of the two plasmids are almost identical except for their antibiotic markers.
The pSKSL-CmR plasmid with a chloroamphenicol (Cm) selectable marker was used to
make the control gap plasmid that does not have a DNA lesion. The pSKSL-KanR
plasmid with a kanamycin (Kan) selectable marker was used to make the lesion gap
plasmid that has a site-specific DNA lesion, either 8-oxo-G or Pt-GG.
The sequence of the pSKSL-KanR plasmid was modified twice by QuikChange® PCR
(Stratagene, 2005). After the first modification, the plasmid was used to construct the
lesion gap plasmid containing 8-oxo-G. Based on the first modification, additional
changes were made in the sequence of the pSKSL-KanR plasmid by a second
QuikChange PCR reaction. The resulting plasmid was used to construct the lesion gap
plasmid containing Pt-GG.

2.2

QuikChange® PCR

Primers were designed for each QuikChange® PCR reaction to make three nucleotide
substitutions in the pSKSL-KanR plasmid. Sequences of the primers for the two
QuikChange® PCR reactions are listed in Table 1. QuikChange® PCR reactions were
carried out as previously described (Stratagene, 2005). Nucleotide substitutions in the
plasmids were confirmed by sequencing.
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Table 1 Primers used in QuikChange PCR reactions to make three nucleotide
substitutions in the pSKSL-KanR plasmid
The first QuikChange® PCR reaction
Template:
pSKSL-KanR plasmid DNA as it was received
Forward
GCCCGTCGTGTAGATAACTAACGTACGGGAGGGCTTACCATC
primer:
(42 bases, GC content 55%, % mismatch to the template: 3/42 bases,
1LG136Tm calculated by the Stratagene formula: 81°C)
oligo 1
Reverse
GATGGTAAGCCCTCCCGTACGTTAGTTATCTACACGACGGGC
primer:
(42 bases, GC content 55%, % mismatch to the template: 3/42 bases,
1LG136Tm calculated by the Stratagene formula: 81°C)
oligo 2
Note:
‘CAG’ in the template was modified to ‘ACG’ as bolded and
underlined in the primer sequences.
The second QuikChange® PCR reaction
Template:
pSKSL-KanR plasmid that has been modified by the first QuikChange®
PCR
Forward
ACTGCCCGTCGTGTAGATAAGTGACGTACGGGAGGGCTTACC
primer:
(42 bases, GC content 57%, % mismatch to the template: 3/42 bases,
4LG94-L
Tm calculated by the Stratagene formula: 82°C)
Reverse
GGTAAGCCCTCCCGTACGTCACTTATCTACACGACGGGCAGT
primer:
(42 bases, GC content 57%, % mismatch to the template: 3/42 bases,
4LG94-R
Tm calculated by the Stratagene formula: 82°C).
Note:
‘CTA’ in the template was modified to ‘GTG’ as bolded and underlined
in the primer sequences. Right after ‘GTG’ is ‘ACG’ from the first
modification.

2.3

Oligonucleotides with site-specific DNA lesions

54mer oligos containing 8-oxo-G were synthesized at the W. M. Keck Oligonucleotide
Synthesis

Facility

(Yale).

The

sequence

of

the

54mer

oligo

is

ACCGCAACGAAGTGATTCCGGCATGCXTCCTACCTGGCTACTTGAACCAGACCG,

where X denotes 8-oxo-G and the sequence of the single stranded gap region is
underlined. The oligos were purified in our lab by anion exchange chromatography using
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a SOURCE 15Q column (GE Healthcare) on ÄKTAFPLC system (GE Healthcare).
54mer oligos containing Pt-GG were made by ligating three shorter oligos (5’-end 21mer,
3’-end 21mer and 12mer) together in the presence of a 34mer scaffold DNA (Table 2).
The

sequence

of

the

54mer

oligo

is

ACCGCAACGAAGTGATTCCGGCTTCCTCTGGCCCTGGCTACTTGAACCAGACCG,

where GG denotes Pt-GG and the sequence of the single stranded gap region is
underlined.
12mer oligos with Pt-GG were made by Chuanbing Bian in our lab following an
established protocol (Zhao et al., 2012). 1.8nmol of the 5’-end 21mer oligos, 1.8nmol of
the 3’-end 21mer oligos and 1.5nmol of the 12mer oligos were 5’-phosphorylated using
T4 polynucleotide kinase (NEB). The three phosphorylated oligos were combined,
annealed to 1.8nmol of the 34mer scaffold oligos, and then ligated using T4 DNA ligase
(NEB) in the presence of 1mM ATP. The 54mer ligated products were separated from
any unligated oligos and scaffold DNAs on an 8M urea 12% polyacrylamide gel. The gel
was ran under constant power of 30-50 Watts for one hour (Figure 5). The 54mer
products were extracted from the gel, purified and re-suspended in a final concentration
of 15pmol/µl.
Table 2 Sequences of the shorter oligos for making the 54mer oligo containing PtGG
5’-end 21mer

ACCGCAACGAAGTGATTCCGG

12mer with Pt-GG (red) CTTCCTCTGGCC
3’-end 21mer

CTGGCTACTTGAACCAGACCG

34mer scaffold

AAGTAGCCGGGGCCAGAGGAAGCCGGAATCACTT

2.4

Construction of double stranded gap plasmids

150pmol of the 54mer oligos, 240pmol of the upstream 15mer primer and 240pmol of the
downstream 15mer primer were 5’-phosphorylated. They were annealed to make gap
duplexes. 150pmol of the gap duplexes were ligated into 100pmol of linearized DNA
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vectors in a large-scale ligation reaction using 60,000 units of T4 DNA ligase in a total
final volume of 12ml. The DNA vectors were prepared by digesting 600µg of the
pSKSL-CmR or p-SKSL-KanR plasmid DNAs with 300 units each of the BsaI and BstXI
restriction enzymes, and isolating the larger DNA fragment (around 3kb) by gel
purification. After ligation, DNA was concentrated by ethanol precipitation. The singly
ligated gap plasmids were separated from any unligated DNA vectors and multiply
ligated DNA products by gel purification and electroeluted. The isolated gap plasmids
were concentrated by ethanol precipitation and desalted using an Amicon Ultra-0.5mL
Microcon® column (Ultracel 3K Membrane, Millipore).

The concentration of the

purified gap plasmids was measured by NanoDrop.
Table 3 Sequences of the two 15mer oligos annealing to the 54mer oligo for making
the gap duplex
Upstream 15mer primer

GGAATCACTTCGTTG

Downstream 15mer primer CTGGTTCAAGTAGCC

2.5

Cell lines and cell culture

Isogenic pairs of immortalized mouse embryonic fibroblast (MEF) cell lines with
knockout(s) of one or a few translesion DNA polymerase genes were obtained (Table 4).
A pair of Burkitt’s lymphoma (BL2) cell lines, one wild type and one POLI-deficient,
was also obtained (Table 4).
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Table 4 Mammalian cell lines with various knockouts of translesion DNA
polymerase genes
Cell line and genotype
MEF POLI (+/+)

MEF POLI (-/-)
BL2 POLI(+/+)
BL2 POLI(-/-)
MEF POLH(+/+)

Nickname
7241SV

7253SC
267
B3

MEF POLH(-/-)
MEF POLK(+/+)
MEF POLK(-/-)
MEF
POLH(-/-) POLI(-/-)
MEF
POLK(-/-) POLI(-/-)
MEF
POLH(-/-) POLI(-/-)
POLK(-/-)
MEF
POLH(-/-) POLI(-/-)
POLK(-/-)
MEF REV1(+/+)

MEF REV1(-/-)
MEF REV3L (+/lox) Cre

2091

2095

3(+)6

Sender / Laboratory

Reference

Dr. Woodgate (National (McDonald et al.,
Institute
of
Child 2003)
Health and Human
Development, USA)
Dr. Woodgate
(McDonald et al.,
2003)
Dr. Woodgate
(Faili et al., 2002)
Dr. Woodgate
(Faili et al., 2002)
K. Hashimoto, Moriya (Ohkumo et al.,
Lab
(Stony Brook 2006)
University, New York)
K. Hashimoto, Moriya (Ohkumo et al.,
Lab
2006)
K. Hashimoto, Moriya (Ogi et al., 2002)
Lab
K. Hashimoto, Moriya (Ogi et al., 2002)
Lab
K. Hashimoto, Moriya (Ohkumo et al.,
Lab
2006)
K. Hashimoto, Moriya (Hashimoto et al.,
Lab
2012)
K. Hashimoto, Moriya (Hashimoto et al.,
Lab
2012)
K. Hashimoto, Moriya (Hashimoto et al.,
Lab
2012)
Dr. Niels de Wind (Jansen, 2006)
(Leiden
University
Medical
Center,
Netherlands)
Dr. Niels de Wind
(Jansen, 2006)
L. Sabine, Wood Lab (Lange et al., 2012)
(MD Madison Cancer
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MEF REV3L (-/lox) Cre
MEF REV3L (-/lox) Cre
MEF
REV3L(+/+) P53(-/-)
MEF
REV3L(-/-) P53(-/-)
MEF
REV3L(-/-) P53(-/-)

4(-)5
4(-)11
B2

Center, Texas)
L. Sabine, Wood Lab
L. Sabine, Wood Lab
L. Sabine, Wood Lab

B4-9

L. Sabine, Wood Lab

B4-18

L. Sabine, Wood Lab

(Lange et al., 2012)
(Lange et al., 2012)
(Wittschieben et al.,
2006)
(Wittschieben et al.,
2006)
(Wittschieben et al.,
2006)

Mouse embryonic fibroblast (MEF) cell lines were cultured in Dulbecco’s Modified
Eagle’s Medium (DMEM) with 4.5g/L glucose and sodium pyruvate, adding 1x
GlutaMAX (Invitrogen), 10% new born calf serum (Wisent), and penicillin (100 IU) and
streptomycin (100ug/ml). Cells were passaged with 0.25% trypsin 2.21mM EDTA
solution. Burkitt’s lymphoma (BL2) cells grow in suspension. BL2 cell lines were
cultured in RPMI 1640 medium with L-glutamine and sodium bicarbonate (Wisent),
adding 10% fetal bovine serum (Wisent), and penicillin (100IU) and streptomycin
(100ug/ml). The cell lines were maintained at 37°C in 5% CO2 environment chamber.

2.6

Transient Transfection

Cells were seeded at a density of 2x105 cells per 35mm dish the day before transfection.
33ng of the control gap plasmids, 33ng of the lesion gap plasmids and 2µg of the carrier
plasmids (pBlueScript) were transfected into cells using jetPRIME® reagent (Polyplus
TransfectionTM), as per manufacturer’s recommendations. Cells were incubated for seven
hours.

2.7

Traditional TLS assay

Mammalian cells that had been transfected with gap plasmids were harvested and washed
three times with PBS. The plasmids were extracted by the alkaline lysis method using a
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plasmid Miniprep kit (Invitrogen). Plasmid DNAs were transformed into E. coli
(CSH117 strain) by electroporation. Bacterial cells were plated in triplicates on
chloramphenicol (30µg/ml) and kanamycine (50µg/ml) plates to separate the control
plasmids and the lesion plasmids, respectively. Translesion synthesis efficiency was
determined by taking the ratio of the average number of bacterial colonies arising on the
kanamycin plates to that arising on the chloramphenicol plates. Isolated bacterial colonies
were inoculated into LB starter cultures and grown overnight. Plasmid DNAs were
extracted and their sequences were determined by Sanger Sequencing.

2.8

Statistical analyses of traditional TLS assay

To determine if the POLI gene has an effect on bypassing 8-oxo-G, two-tailed Fisher’s
Exact Test (Fisher, 1922) was used to determine if the number of sequences with
mutation across from a DNA lesion of the POLI wild type cell line is significantly
different from that of an isogenic POLI-deficient cell line. A two by two contingency
table was set up for computing the exact P-value (Weisstein), whereby the two groups
compared are POLI wild type cell line and its isogenic POLI(-/-) cell line and the two
outcomes are “no mutation” and “with mutation” across from the DNA lesion. If the
computed P-value is less than α of 0.05, the difference in observations between the two
cell lines is deemed statistically significant. The same method was used to determine if
the POLH gene and the POLI gene each had an effect on bypassing Pt-GG.

2.9

Quantitative PCR

Q-PCR reactions were used to measure copy numbers of the control plasmids and lesion
plasmids extracted from mammalian cells. The ratio of the number of copies of the lesion
plasmids to that of the control plasmids (Kan/Cm) is the translesion synthesis efficiency.
A 72 bp fragment of the chloramphenicol resistant gene of the control plasmids and a 71
bp fragment of the kanamycin resistant gene of the lesion plasmids were amplified using
the primers listed in Table 5. Melting curve analyses showed that the primers were

25

specific for amplifying their respective targets. Standard curves were plotted using known
concentrations of each of the control plasmids and lesion plasmids from 5ng/µl to 5x106

ng/µl in ten-fold serial dilutions. Concentrations of unknown samples were interpolated

from the standard curves.
Table 5 Sequences of Q-PCR primers used to measure copy numbers of the control
plasmids and the lesion plasmids extracted from mammalian cells
Primers amplifying from the control plasmids
Left

GGGAAATAGGCCAGGTTTTC (20bp, Tm=59.8°C, GC content 50%)

Right

CGATTTCCGGCAGTTTCTAC (20bp, Tm=59.7°C, GC content 50%)

Primers amplifying from the lesion plasmids
Left

AGAAACAACTCTGGCGCATC (20bp, Tm=60.4°C, GC content 50%)

Right

GATAATGTCGGGCAATCAGG (20bp, Tm=60.3°C, GC content 50%)

In an earlier experiment, four DNA samples (3LG188.1, 3LG188.2, 3LG102.5 and
3LG102.6) were measured. A typical Q-PCR reaction consisted of 2µl left primer (1µM
stock), 2µl right primer (1µM stock), 1µl DNA extracted from mammalian cells or 1µl
DNA standard, and 5µl 2x EvaGreen qPCR Master Mix. Reactions were set up in
replicates and ran on Eppendorf RealPlex Mastercycler. The thermocycling condition
was 95°C 2 min, 35 cycles of 95°C 20 s, 57°C 20 s and 72°C 35 s, then 72°C 10 min.
In a later experiment, the translesion synthesis efficiencies of 8-oxo-G and Pt-GG were
determined from each of the nine MEF cell lines with the following genotypes:
POLI(+/+), POLI(-/-), POLH(+/+), POLH(-/-), POLK(+/+), POLK(-/-), POLH(-/-) and
POLI(-/-), POLK(-/-) and POLI(-/-), and 2091 POLH(-/-) POLK(-/-) and POLI(-/-). For
each cell line, three biological replicates were used and each biological replicate was
measured in triplicates. Q-PCR reactions were set up on a 384-well plate using SYBR
Select Master Mix (Invitrogen) and ran on the ViiA7TM Real-Time PCR System. The
thermocycling condition was 50°C 2 min, 95°C 2 min, 95°C 15 s, 40 cycles of 95°C 15 s,
57°C 15 s and 72°C 1 min.
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2.10 High-throughput TLS assay
The gap regions of the plasmids extracted from mammalian cells were amplified by PCR
using primers that contain barcodes and Illumina adapter sequences. Twenty-four
barcodes were embedded in left primers and right primers, respectively. The primers
were ordered from Integrated DNA Technologies in 25nmole scale.
In the 8-oxo-G study, the control plasmids and lesion plasmids of a transfection
experiment were amplified in the same PCR reaction. They would be separated
computationally based on a three nucleotide difference in their sequences. The sequence
of the plasmid-specific portion of the left primer is GACTGCCCGTCGTGTAGATAA,
and

that

of

the

plasmid-specific

portion

of

the

right

primer

is

AGCGGTCTGGTTCAAGTAGC. A PCR reaction was set up using 11.8µl water, 4µl 5x
HF Phusion buffer (Thermo Scientific), 0.4µl 10mM dNTP, 0.8µl left primer (5uM
stock), 0.8µl right primer (5uM stock), 2µl plasmid DNA extracted from mammalian
cells, and 0.2µl Phusion Hot Start DNA Polymerase (2U/µl, Thermo Scientific). The
thermocycling condition was 98°C 30 s, 25 cycles of 98°C 10 s, 66°C 20 s and 72°C 15 s,
and lastly 72°C 5 min. There are 192 transfection experiments in the 8-oxo-G study,
including nine biological replicates for each of the twenty cell lines and positive and
negative controls.
In the Pt-GG study, the control plasmids and the lesion plasmids of a transfection
experiment were amplified in two separate PCR reactions using different left primers and
a common right primer. The sequence of the plasmid-specific portion of the left primer
used to amplify the control plasmid is CCCGTCGTGTAGATAACTACGA, and that
used to amplify the lesion plasmid is GCCCGTCGTGTAGATAAGTGA. The sequence
of the right primer is the same as that used in the 8-oxo-G study. A typical PCR reaction
consisted of 8.2µl water, 4µl 5x HF Phusion buffer, 0.6µl DMSO, 0.4µl 10mM dNTP,
0.8µl left primer (5uM stock), 0.8µl right primer (5uM stock), 5µl plasmid DNA
extracted from mammalian cells and 0.2µl Phusion Hot Start DNA Polymerase (2U/µl).
Two rounds of DNA amplifications were carried out for a total of 55 PCR cycles. The
first PCR reaction was ran 98°C 30 s, 25 cycles of 98°C 10 s and 72°C 15 s, and ended at
72°C 5 min. DNA products were purified and then used as templates in the second PCR
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reaction. There are 384 barcoded samples in the Pt-GG study. They came from 192
transfection experiments, including nine biological replicates for each of the twenty cell
lines and positive and negative controls.
PCR products of the 8-oxo-G and Pt-GG studies were purified, and their concentrations
were measured using a Qubit® dsDNA High Sensitivity Assay Kit (Invitrogen). 10ng of
each of the 576 barcoded DNA samples were combined and further concentrated, then
the DNA sample was sequenced using 2 by 150 Illumina MiSeq (Robarts Institute).

2.11 Processing Next Generation Sequencing raw data
Two FASTQ files were generated from the MiSeq run (Appendix 4), one file contains
reads sequenced in the forward direction (R1) and the other file contains reads sequenced
in the reverse direction (R2). Each file was processed independently following the same
procedures. Briefly, reads of the PhiX genome were removed using BOWTIE2, a read
alignment tool (Langmead and Salzberg, 2012). FASTQ/A Short-reads Pre-processing
Tools (Hannon Lab, Cold Spring Harbor Laboratory) were used to trim, clip and split
data. Reads with the same barcodes were grouped and then further split into control
plasmids and lesion plasmids, and those that don’t match to barcodes were discarded. All
the sequences were trimmed to 25 bases including the 12-nucleotide gap region. Base
substitutions of every nucleotide in the gap region were tallied using a ‘NGS Position
Counter’ program (Taggart et al., 2013). To count the number of reads of different
permutations of dinucleotides, such as those opposite the Pt-GG lesion, a Perl script
given to me by Greg Gloor was used to parse the data.

2.12 Statistical analyses of Next Generation Sequencing data
The same care was taken to analyze reads of the control plasmids and reads of the lesion
plasmids. The overall mutation frequencies across from 8-oxo-G or Pt-GG were
calculated based on the sum total of reads obtained for each DNA lesion, regardless of
the genotype of cell lines. The mutation frequency of the lesion plasmids was compared
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to that of the control plasmids to elucidate the effect of a DNA lesion. To understand how
the mutation spectrums differ between the control plasmids and the lesion plasmids,
principal component analysis (Aitchison, 2003) was applied. The CoDaPack Software
2.01 (Comas-Cufi and Thió-Henestrosa, 2011) and the compositions package in R (van
den Boogaart and Tolosana-Delgado, 2008) were used to generate biplots. A biplot shows
the correlations among variables between the control plasmids and the lesion plasmids,
and the relative proportions of changes in the variables effected by a DNA lesion.
To infer the biological function of a translesion DNA polymerase on the bypass of a
certain DNA lesion, results from two isogenic cell lines were compared. See Appendix E
for a list of all the cell lines compared, both for the control plasmids and for the lesion
plasmids in the high-throughput TLS assay. For each cell line and for each of its nine
biological replicates, the within-sample ratios were calculated and log2 transformed. In
the 8-oxo-G study, the within-sample variables are log2(A/C), log2(T/C), log2(G/C) and
log2(deletion/C). In the Pt-GG study, the within-sample variables are log2(CT/CC),
log2(AT/CC), log2(CG/CC), log2(AG/CC), log2(C/CC), log2(TC/CC), log2(GC/CC),
log2(AC/CC), log2(A/CC), log2(CA/CC), log2(AA/CC), log2(double deletions/CC).
Wilcoxon Rank Sum Test was used to compare each of the variables between a pair of
isogenic cell lines (N=9) and to calculate P-values. P-values were adjusted by the
Benjamini-Hochberg method (Benjamini and Hochberg, 1995). Where the adjusted Pvalues were less than 0.05 (α), the effect sizes (Cohen’s d) and their 95% confidence
intervals (C.I.) were calculated and the biological functions of the translesion DNA
polymerases were deduced based on the genotypes of the cell lines being compared.
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Chapter 3
3

Results

3.1

Construction of double stranded gap plasmids containing an 8oxo-G or Pt-GG lesion

To study mutations in mammalian cells caused by a DNA lesion, I constructed double
stranded gap plasmids containing a site-specific 8-oxo-G or Pt-GG lesion. The gap
plasmids were transfected into mammalian cells as the first step in the translesion
synthesis assay. To produce double stranded gap plasmids, gapped duplexes were ligated
into double stranded DNA vectors as shown in Figure 4. Each gap duplex was formed by
annealing two short primers to a 54 mer oligonucleotide containing a DNA lesion. The
54mer oligo was produced by bridging together three shorter oligos that had been 5’phosphorylated, in the presence of a 34mer scaffold DNA, and the final product was
purified by denaturing PAGE (Figure 5). DNA vectors were prepared by digesting 600µg
of the pSKSL-CmR or p-SKSL-KanR plasmid DNAs with 300 units each of the BsaI and
BstXI restriction enzymes and isolating the larger DNA fragment (around 3kb) by gel
purification. 150pmol of the gap duplexes were ligated into 100pmol of linearized DNA
vectors in a large-scale ligation reaction using 60,000 units of T4 DNA ligase in a total
final volume of 12ml. After ligation, DNA was concentrated by ethanol precipitation and
then the singly ligated gap plasmids were separated from any unligated DNA vectors and
multiply ligated DNA products by gel purification (Figure 6), and electroeluted using
dialysis bags. The isolated gap plasmids were concentrated by ethanol precipitation and
desalted using an Amicon Ultra-0.5mL Microcon® column (Ultracel 3K Membrane,
Millipore). The gap plasmids prepared transfected with high efficiency into mouse
embryonic fibroblast cells. Control gap plasmids without DNA lesions were produced in
a similar way.
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Figure 4 Gap plasmids were made by ligating gap duplexes into linear DNA vectors
A 54mer oligonucleotide with or without a site-specific DNA lesion was produced by
ligating three shorter oligonucleotides that were phosphorylated at the 5’-end and that
were annealed to a 34mer scaffold oligo. The 54mer oligo was gel purified (Figure 5) and
then annealed to two primers to form a gap duplex, which was then ligated into a DNA
vector to form a double stranded plasmid with a small single stranded gap (Figure 6).

Figure 5 Isolating 54mer oligos containing a site-specific DNA lesion by gel
purification
8M urea 12% PAGE. Lane 1 and 2 were loaded with the ligation reaction—ligation of
three oligonucleotides annealed to 34mer scaffold oligos. Lane 3 was loaded with the
scaffold DNA only. Lane 4 was loaded with a tracking dye.
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Figure 6 Gap plasmids produced from a large-scale ligation reaction
Singly ligated gap plasmids (marked by *) ran at 4kb in 0.8% agarose gel made with
1xTAE buffer. Lane 2: an aliquot of the large-scale ligation reaction—ligation of gapped
duplexes into DNA vectors; Lane 3: DNA vectors only. In gel purification of the largescale ligation reaction, DNA bands stained with ethidium bromide were visualized under
short wavelength UV light. Exposure to UV light was kept to minimum to prevent
formation of pyrimidine dimers.

3.2

8-oxo-G caused a high frequency of mutation

To determine the mutation frequency of an 8-oxo-G lesion, gap plasmids containing the
lesion were co-transfected with control gap plasmids without the lesion into mouse
embryonic fibroblast cells and BL2 cells. The mutation frequency of 8-oxo-G was
determined by the traditional TLS assay and by the high-throughput TLS assay.
In the traditional TLS assay, gap plasmids that had been repaired were retrieved from
mammalian cells and then transformed into E. coli for amplification. The control
plasmids and lesion plasmids were separated by plating the transformed bacterial cells on
chloramphenicol plates and on kanamycin plates, respectively. Isolated bacterial colonies
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arising on the plates were grew in starter cultures and the plasmid DNAs were extracted
and sent for sequencing. In the high-throughput TLS assay, the gap regions of the
plasmids retrieved from mammalian cells were amplified by PCR and then sequenced;
the control plasmids and lesion plasmids were separated based on a three-nucleotide
difference in their sequence.
In the traditional TLS assay, the mutation probability of 8-oxo-G was 64 out of 174
sequences analyzed (36.8%) for MEF cells, and 41 out of 182 sequences analyzed
(22.5%) for BL2 cells. There were no mutations across from a regular G nucleotide in the
control plasmids, where 60 control plasmid sequences were analyzed for the MEF cell
type and for the BL2 cell type, respectively.
In the high-throughput TLS assay, the mutation frequency of 8-oxo-G or that of a regular
G nucleotide was the same between MEF cells and BL2 cells. The mutation frequency of
8-oxo-G was 91% from a total of 319,777 reads analyzed (279,650 reads for MEF cells
and 40,127 reads for BL2 cells), and that of a regular G nucleotide was 1.6% from a total
of 541,965 reads analyzed (461,711 reads for MEF cells and 80,254 reads for BL2 cells).
The background error rate determined as the average of three positive control
experiments where a fully double stranded plasmid with known sequence was used as
template in PCR reactions was 0.09%.

3.3

Almost all the mutations caused by 8-oxo-G were C->A
substitutions

The mutation spectrum of 8-oxo-G was determined by the traditional TLS assay and by
the high-throughput TLS assay. Most of the mutations formed across from 8-oxo-G were
C->A substitutions. In the traditional TLS assay, 93% of mutations (60/64 sequences)
opposite to the lesion transfected into MEF cells were C->A substitutions, 5% (3/64
sequences) were C->G substitutions and 2% (1/64 sequences) were C->T substitutions;
all of the mutations opposite to the lesion transfected into BL2 cells were C->A
substitutions (38/38 sequences).
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In the high-throughput TLS assay, 99% of all the mutations across from 8-oxo-G were C>A substitutions and only 1% were C->G substitutions (Figure 7). Furthermore, principal
component analysis of the NGS data shows that, first of all, reads of the control plasmids
and reads of the lesion plasmids are highly separable based on their nucleotide
compositions at the position of the DNA lesion (Figure 8); second, the major difference
between the control plasmid and the lesion plasmid is in the frequency of C->A
substitutions; third, change in the variable C (inserted against a regular nucleotide G) in
the control plasmids is linearly correlated to changes in the variables A and G (inserted
opposite to 8-oxo-G) in the lesion plasmids at different proportions (Figure 8). The
variable C is weakly correlated to the variable T and uncorrelated to the variable deletion
(Figure 8). Principal component analysis indicates that 8-oxo-G caused purine bases,
mostly A to be incorporated thus producing transverion mutations.

Figure 7 Mutation frequency and mutation profile of 8-oxo-G in mammalian cells.
Results of the high-throughput TLS assay show that while C was correctly inserted to a
regular G nucleotide in the control plasmids, A was misincorporated against 8-oxo-G in
the lesion plasmids and the mutation frequency of 8-oxo-G was 91%. 541,965 reads were
analyzed for the control plasmids and 319,777 reads were analyzed for the lesion
plasmids.
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Figure 8 Biplot generated from principal component analysis of the 8-oxo-G data
Principal component analysis (PCA) reduces a high dimensional or multivariate dataset
into a smaller number of linearly uncorrelated variables called principal components
through orthogonal transformation of the data. The transformation is defined in such a
way that the first principal component contains the largest possible variance and
subsequent principal components contain the largest possible variance under the
constraint that they are uncorrelated to the previous principal components (Aitchison,
2003). Through PCA the data is placed in a new dimension and is deconstructed into
eigenvectors and eigenvalues that form the principal components. Eigenvectors and
values exist in pairs with the eigenvector indicating the direction and the eigenvalue
indicating the spread of the data in that direction. In simpler terms, PCA reveals the
underlying structure of the data and divides the variance of the data into directions that
are perpendicular or principal components that are uncorrelated to each other. A biplot
displays experimental observations and variables of an experiment on the same plot. Each
point in the biplot is data of a transfection experiment. The raw experimental data was
converted into compositional data by first taking log-ratios and then applying center log
transformation (clr). PCA does not lose the relative scaling of the original variables. In
the 8-oxo-G study, reads of the control plasmids are well separated from reads of the
lesion plasmids along principal component one that accounts for 88.4±2.76% of total
variance of the data. This proves that constructions of the control and the lesion double
stranded gap plasmids were successful. While the magnitude of composition vectors
shows the relative proportion of variables, the direction of composition vectors shows the
correlation among different variables. Data points for the control plasmids (blue dots) are
largely driven by C incorporated across from a regular G nucleotide and those for the
lesion plasmids (red dots) are driven by A incorporated against 8-oxo-G. Because a
change in the variable C is highly correlated to changes in the variables A and G, 8-oxoG caused transversion mutations.
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3.4

There was no apparent biological function of Pol iota in the
bypass of 8-oxo-G

Because 8-oxo-G is a very abundant and highly mutagenic DNA lesion (van Loon et al.,
2010), DNA polymerases that can correctly bypass the lesion are biologically important.
Pol iota is one of the most error-prone DNA polymerases in eukaryotes (Tissier et al.,
2000; Zhang et al., 2000a; Kirouac and Ling, 2011b; Makarova and Kulbachinskiy,
2012). Previous structural findings demonstrated that Pol iota correctly bypasses 8-oxo-G
in vitro, thus pointing to a plausible biological function of the DNA polymerase (Kirouac
and Ling, 2011a).
To investigate the function of Pol iota in the bypass of 8-oxo-G in mammalian cells, I
used both the traditional TLS assay and the high-throughput TLS assay. For each assay
the mutation frequency of 8-oxo-G of a POLI wild type cell line was compared to that of
a POLI-deficient cell line to deduce Pol iota’s function. In the traditional TLS assay, the
mutation probability of 8-oxo-G was 33 out of 89 sequences analyzed (37%) for the MEF
POLI wild type cell line and 31 out of 85 sequences analyzed (37%) for the MEF POLI(/-) cell line, so Pol iota did not have an effect on bypassing the lesion in MEF cells (Pvalue=1, Fisher’s Exact Test, α=0.05). Also in the traditional TLS assay, the mutation
probability of 8-oxo-G was 17 out of 93 sequences analyzed (18%) in the BL2 wild type
cell line and 24 out of 89 sequences analyzed (27%) in the BL2 POLI(-/-) cell line. Pol
iota also did not play a role in the correct bypass of the lesion in BL2 cells (Pvalue=0.2139, Fisher’s Exact Test, α=0.05).
In the high-throughput TLS assay, there was no difference in the mutation frequency of
8-oxo-G between the MEF POLI(+/+) wild type cell line and the MEF POLI(-/-) cell line
nor between the BL2 wild type cell line and the BL2 POLI(-/-) cell line. Therefore, it was
not likely that Pol iota bypassed 8-oxo-G in mammalian cells. The reason for this result
could be that the function of Pol iota was redundant with those of other DNA
polymerases and that Pol iota’s activity was minor compared to those of other DNA
polymerases so its effect could not be detected in mammalian cells.
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3.5

Pol eta correctly bypassed 8-oxo-G in vivo

To determine the functions of Pol iota, Pol eta, Pol kappa, Rev1 and Rev3L on the bypass
of an 8-oxo-G lesion in mammalian cells, I used the high-throughput TLS assay that
incorporated the use of Next Generation Sequencing. The high-throughput TLS assay
shows that Pol eta, among the five translesion DNA polymerases tested correctly
bypassed 8-oxo-G in vivo.
To deduce the function of Pol eta, I compared the mutation frequency of 8-oxo-G
between the MEF POLH(+/+) cell line and the MEF POLH(-/-) cell line, where there
were nine transfection experiments set up for each cell line. Similarly, to deduce the
function of Pol kappa, I compared between the MEF POLK(+/+) cell line and the MEF
POLK(-/-) cell line; to deduce the function of Rev1, I compared between the MEF
REV1(+/+) cell line and the MEF REV1(-/-) cell line. To deduce the function of Rev3L, I
compared the 3(+)6 REV3L(+/lox) cell line to each of the 4(-)5 and 4(-)11 cell lines that
have the genotype REV3L(-/lox); and compared the B2 REV3L(+/+) P53(-/-) cell line to
each of the B4(-)9 and B4(-)18 cell lines that have the genotype REV3L(-/-) P53(-/-). To
uncover synergistic effects of the translesion DNA polymerases, I compared each of the
POLI(+/+), POLH(+/+) and POLK(+/+) wild type cell lines to the two double knockout
cell lines with the genotypes POLH(-/-)POLI(-/-) and POLK(-/-) POLI(-/-), respectively.
Moreover, I compared each of the POLI(-/-), POLH(-/-) and POLK(-/-) single knockout
cell lines to the two triple knockout cell lines named 2091 and 2095, respectively, that
have the genotype POLH(-/-)POLI(-/-)POLK(-/-). The reader may refer to Appendix E
for a list of all the cell lines compared in the high-throughput TLS assay.
I focused on analyzing the frequency of C->A substitutions across from 8-oxo-G because
the frequencies of C->G and C->T substitutions were negligible. When processing the
NGS data, I took the within-sample ratio A to C—the proportion of reads with A to those
with C for a given transfection experiment. This normalized the data to one and cancelled
out any experimental errors. Then the A/C ratio was log2 transformed to express the
proportion of reads with A to those with C as fold changes. The log2 transformed A to C
ratios of nine biological replicates of a cell line were compared to those of the nine
biological replicates of the other cell line by the Wilcoxon Rank Sum Test. I used this
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statistical test because it does not make assumption about the data distribution. The
Wilcox Rank Sum Test evaluates the likelihood that the median of the nine log2(A/C)
ratios of a wild type cell line and that of the nine log2(A/C) ratios of its isogenic mutant
cell line were from two different populations. In my case, the test is interpreted as the
probability that the translesion DNA polymerase(s) in question, which is the only
difference between the two isogenic cell lines compared, affected the mutation frequency
of 8-oxo-G. P-values calculated by Wilcox Rank Sum Tests were adjusted by the
Benjamini-Hochberg method (Benjamini and Hochberg, 1995) to keep Type I error in
check. The chance of falsely rejecting a null hypothesis is one in twenty when alpha of Pvalue is set at 0.05, but when the number of statistical tests performed increases, so is the
likelihood of making false positive inferences. Benjamini-Hochberg (BH) method
controls for false positive findings of a study that involves multiple comparisons by
scaling P-values, so the overall false discovery rate (the ratio of the false positives to true
positives) of the study is kept low, say at 5% when alpha of the BH-adjusted P-value is
chosen at 0.05. Where the adjusted P-value was less than 0.05, the difference between
two isogenic cell lines was deemed statistically significant and the effect size (Cohen’s d)
and its 95% confidence interval (C. I.) were calculated. Cohen’s d expressed the
difference in mutation frequency of 8-oxo-G between two isogenic cell lines in units of
standard deviation. An effect size of 0.6 or greater is considered large by convention.
The 8-oxo-G study and bypass of the DNA lesion by five translesion DNA polymerases
took up 9% of the total sequencing capacity. The number of reads obtained for each
transfection experiment is shown in Figure 9. The most significant finding of the highthroughput study is that Pol eta correctly bypassed 8-oxo-G. Compared to the MEF
POLH(+/+) cell line, knocking out the POLH gene alone or knocking out the POLH gene
along with the POLI gene led to more frequent C->A substitutions across from an 8-oxoG lesion but not across from a regular G nucleotide (Figure 10).
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Figure 9 Reads obtained for every transfection experiment in the 8-oxo-G study
The number of reads for the control plasmid and that for the lesion plasmid are shown for
every transfection experiment in the 8-oxo-G study (see Appendix F for raw data). For a
given DNA sample extracted from mammalian cells, the control plasmids and the lesion
plasmids were amplified in the same PCR reaction (for a total of 25 cycles) and thus their
reads were labelled with the same barcodes; the reads were split based on a three
nucleotide difference in their sequences close to the gap region. Data for a total of 192
transfection experiments are shown. They include nine biological replicates for each of
the twenty cell lines listed in Table 4, and positive and negative controls done in
triplicates. Positive control PCR reactions used the control plasmid (without gap) as
template. There are two types of negative control experiments: in the first type, no
transfection reagent was added, as a result none of the gap plasmids entered into
mammalian cells and during alkaline lysis, the gap plasmids were denatured and
eliminated; in the second type, no DNA template was added in PCR reactions. The
purpose of this graph is to present raw data for the 8-oxo-G study and to show how the
NGS capacity was divided among transfection experiments. There are more reads for the
control plasmid than for the lesion plasmid, indicating that the control plasmid is filled
more efficiently than the lesion plasmid in mammalian cells; this point will be examined
in more detail in Section 3.12.
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Figure 10 The role of POLH on the bypass of 8-oxo-G
Knocking out the POLH gene alone or knocking out the POLH gene along with the POLI
gene led to more frequent C->A substitutions. The forest plot shows the effect size and
the Benjamini-Hochberg (BH) adjusted P-value for comparisons made between the
POLH(+/+) wild type cell line and each of the POLH(-/-) single knockout and the
POLH(-/-) POLI(-/-) double knockout (DKO) cell lines.

Besides Pol eta, another translesion DNA polymerase Rev3L correctly bypassed 8-oxo-G
lesion in one of the four pairs of REV3L cell lines analyzed. Knocking out the REV3L
gene in a P53 null genetic background resulted in more frequent C->A substitutions
against an 8-oxo-G lesion but not against a regular G nucleotide (Table 6).
Table 6 The effect of REV3L on the bypass of 8-oxo-G
Cell lines (N=9 groups)
REV3L(+/+) P53(-/-) versus REV3L(-/-) P53(-/-)
Nick name: B2 versus B4(-)18

Adjusted
P-value
0.023

Cohen’s
d
-2.05

95% C. I.
-3.38 to -0.71

Pol kappa and Rev1 had no effects on bypassing 8-oxo-G. Results were validated by the
NGS data sequenced from the opposite direction (see Appendix A).
Given that the mutation frequency of 8-oxo-G was found to be 91% in the highthroughput TLS assay, the finding that Pol eta was the major DNA polymerase in mouse
embryonic fibroblasts to correctly bypass the lesion is biologically important. Efficient
and accurate replication of 8-oxo-G by the yeast Pol eta and the human Pol eta have been
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reported, whereas the role of Rev3L in the tolerance of 8-oxo-G has not been
characterized.

3.6

The mutation frequency of Pt-GG was similar to that of
regular GG dinucleotides

To determine the mutation rate of Pt-GG I used both the traditional TLS assay and the
high-throughput TLS assay. Gap plasmids containing Pt-GG lesions were co-transfected
with control gap plasmids without lesions into mouse embryonic fibroblast cells. In the
traditional TLS assay, gap plasmids that had been repaired in mammalian cells were
amplified by E. coli and then sequenced. The average mutation probability of Pt-GG was
19 out of 110 sequences analyzed (17.3%) for the first insertion step, 6 out of 110
sequences analyzed (5.4%) for the second insertion step, and overall, 25 out of 110
sequences analyzed (22.7%). There were no mutations across from regular GG
dinucleotides in the control plasmids from a total of 35 sequences analyzed.
In the high-throughput TLS assay, the gap region of the plasmids that had been repaired
in mammalian cells were amplified by PCR. The mutation frequency of Pt-GG was
21,520 reads out of 4,491,510 reads analyzed (4.79x10-3) and that of regular GG
dinucleotides was 38,212 reads out of 5,901,558 reads analyzed (6.47x10-3). The
experimental error rates were 2.05x10-3 for the lesion plasmids (Table 7) and 2.65x10-3
for the control plasmids (Table 8) determined from positive control experiments. The
mutation frequency of Pt-GG was similar to that of a regular GG dinucleotides and was
equal to two times the background error rate of the experiment.
Table 7 Determining the background error rate for amplifying Pt-GG lesion
plasmids.
Positive PCR reactions for
Pt-GG control plasmids
L24R16
L24R17
L24R18

Total reads obtained for
the sample

25996
20242
25642
Average error rate 0.00205

Number of reads
containing errors across
from GG dinucleotides
65
36
48

41

Table 8 Determining the background error rate for amplifying Pt-GG control
plasmids.
Positive PCR reactions for
Pt-GG control plasmids
L23R16
L23R17
L23R18

3.7

Total reads obtained for
the sample

46450
52032
47291
Average error rate 0.002652

No. of reads containing
errors across from GG
dinucleotides
127
144
116

Mutation spectrum of Pt-GG

To determine what nucleotides were incorporated across from Pt-GG, I used the
traditional TLS assay and the high-throughput TLS assay. The most abundant mutation
arising from Pt-GG lesion was CC->AC substitution. In the traditional TLS assay, most
of the mutations were CC->AC substitutions: 19 out of 25 sequences that have mutations
had A mis-inserted at the first insertion step to the DNA lesion, the other 6 sequences
have mutation at the second insertion step (see Table C-2, Figure C-1 and C-2 in
Appendix C). In the high-throughput TLS assay, among the 21,520 reads that have
mutations across from the Pt-GG lesion, 50% are CC->AC substitutions, 12% are CC>TC substitutions (Figure 11). Interestingly, in the control plasmids among the 38,212
reads that have mutations, close to 70% have a single nucleotide deletion at one of the
two ‘G’ positions; while in the lesion plasmids, only 15% of the reads with mutations
have a single nucleotide deletion (Figure 11). Compare the mutation spectrum of Pt-GG
to that of GG, there are large increases in the proportions of reads with CC->AC, AT, AA
substitutions, small increases in the proportions of reads with CC->TC, CT, CA
substitutions (Figure 11) and a small decrease in the proportion of reads with double base
deletions.

42

Figure 11 Mutation spectrums across from Pt-GG lesion and GG dinucleotides in
mammalian cells
Mutations across from GG dinucleotides in the control plasmids and Pt-GG in the lesion
plasmids were measured by the high-throughput TLS assay. The mutation spectrums are
derived from 38,212 reads of the control plasmids and 21,520 reads of the lesion
plasmids. In the legend, both ‘A’ and ‘C’ denote a single nucleotide deletion at one of the
two nucleotide positions of GG or Pt-GG. ‘dd’ stands for double base deletion. 70% of
the mutations found opposite to GG in the control plasmids are a single nucleotide
deletion. 65% of the mutations caused by Pt-GG are mis-incorporations of A at the first
insertion step with or without a mutation at the second insertion step. Incorporations of
two purine bases to the Pt-GG lesion are rare; CC->AG and CC->AA substitutions across
from the lesion are much less favored compared to other types of mutations and CC->GA
and CC->GG substitutions are not found.

Despite their similar mutation frequencies, Pt-GG and the regular GG dinucleotides have
different mutation patterns. Principal component analysis of the NGS data shows that the
mutation spectrum of GG in the control plasmids and that of Pt-GG in the lesion plasmids
are separable (Figure 12A). The length of a composition vector in Figure 12B indicates
the relative proportion of change in a variable. For example, compared to the GG
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dinucleotides, Pt-GG causes a large decrease in the frequency of deletions (both a single
nucleotide deletion and a double base deletion) and large increases in the frequencies of
mutations CC->AC, AT, AA and AG. The variables AC, AT and AA that form a cluster
in Figure 12B could be interpreted as being produced by the same molecular mechanism.
In other words, the mutations CC->AC, AT and AA could be produced by the same DNA
polymerase or DNA polymerases recruited by a common pathway.

Figure 12 Biplot generated from principal component analysis of the Pt-GG data
Principal component analysis (PCA) reveals the underlying structure of a compositional
multivariate dataset by reducing its complexity. PCA highlights those variables that
explain the most variance in the data. Principal Component 1 of the biplot, the x-axis
explains 43±1.52% of the total variance in the data and Principal Component 2, the y-axis
explains 10±0.73% of the total variance in the data. A) Each point represents data from a
transfection experiment. Mutation profiles opposite to ‘GG’ (blue dots) are separable
from those opposite to Pt-GG (red dots). This indicates that constructions of the control
plasmids and the lesion plasmids for the Pt-GG study were successful. B) The same
biplot as shown in A) with composition vectors only. Changes in the variables ‘C’ and
‘dd’ of the control plasmids are correlated to changes in the variables ‘AC’, ‘AT’, ‘AA’
and ‘AG’ of the lesion plasmids. The AC, AT, AA variants are highly correlated because
the distance between the tips of the rays is small. ‘Clr.’ stands for centered log-ratio
transformation. ‘dd’ stands for double deletion mutation. The biplots were generated by
the CoDaPack software (Comas-Cufi and Thió-Henestrosa, 2011).
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3.8

The role of Pol eta by itself in the bypass of Pt-GG in vivo

Pt-GG is a major type of cisplatin-DNA adducts found in cancer patients treated with the
drug cisplatin (Cepeda et al., 2007; Fichtinger-Schepman et al., 1987; Jung and Lippard,
2007). Pt-GG is considered a bulky DNA lesion because it involves crosslinking of two
neighboring purines. Due to its large size Pt-GG is thought to be highly blocking to DNA
replication and is thought to be largely responsible for the drug action of cisplatin
(Vaisman et al., 2000; Chijiwa et al., 2010). DNA polymerases with the abilities to
bypass Pt-GG are undesirable in chemotherapy, because their up-regulations are believed
to increase drug resistance to cisplatin. My aim is to identify translesion DNA
polymerases that can bypass the Pt-GG lesion because presumably, inactivating these
DNA polymerases could benefit cancer treatment.
Recently, it has been shown that Pol eta correctly bypasses Pt-GG in vitro (Ummat et al.,
2012; Zhao et al., 2012). To investigate whether Pol eta has a similar function in
mammalian cells, I used the traditional TLS assay and the high-throughput TLS assay to
deduce the biological function of Pol eta. Gap plasmids containing a site-specific Pt-GG
lesion were co-transfected with control gap plasmids without the lesion into a pair of
isogenic MEF cell lines with the genotypes POLH(+/+) and POLH(-/-), respectively.
In the traditional TLS assay, the mutation probability of Pt-GG was 4 out of 29 sequences
analyzed (14%) in the MEF POLH(+/+) cell line and 10 out of 28 sequences analyzed
(36%) in the MEF POLH(-/-) cell line. Notably, the incidence of C->A substitution at the
first insertion step increased by three times when the POLH gene was knocked out and
that at the second insertion step was unaffected (Appendix C, Figures C-6). This suggests
that Pol eta correctly bypassed Pt-GG at the first insertion step (P-value=0.0411, Fisher’s
Exact Test, α=0.05).
In the high-throughput TLS assay, the mutation frequency of Pt-GG was the same in the
MEF POLH(+/+) cell line and in the MEF POLH(-/-) cell line, so Pol eta’s effect on
bypassing Pt-GG was not detected. Using the double and triple knockout cell lines,
however, it could be inferred that Pol eta and Pol iota together promoted CC->AC and
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CC->AT substitutions across from the lesion (Section 3.11), so Pol eta bypassed Pt-GG
in an error-prone manner in vivo.
The function of Pol eta deduced from the traditional TLS assay was supportive of recent
structural reports (Ummat et al., 2012; Zhao et al., 2012), but it was not confirmed by the
high-throughput TLS assay. However, an earlier structural study has shown that Pol eta
incorporates the correct dCTP at the first insertion step to Pt-GG but it cannot incorporate
any nucleotides in the second insertion step to the lesion in vitro; therefore, Pol eta cannot
carry out translesion synthesis of Pt-GG (Chijiwa et al., 2010). This conclusion is
consistent with my finding of Pol eta’s cellular function in the high-throughput TLS
assay.

3.9

The role of Pol iota by itself in the bypass of Pt-GG in vivo

The POLI gene arises from an ancestral gene duplication of the POLH gene. To
determine if Pol iota could bypass Pt-GG in vivo, I used the traditional TLS assay and the
high-throughput TLS assay to deduce the biological function of Pol iota in mammalian
cells. Lesion gap plasmids containing a Pt-GG lesion were co-transfected with control
gap plasmids without the lesion into a pair of isogenic MEF cell lines with the genotypes
POLI(+/+) and POLI(-/-), respectively.
In the traditional TLS assay, the mutation probability of Pt-GG was 7 out of 29 sequences
analyzed (24%) in the MEF POLI(+/+) cell line and 4 out of 24 sequences analyzed
(16.5%) in the MEF POLI(-/-) cell line. Knocking out the POLI gene did not affect the
probability of mutation at the first insertion step (P-value=1, Fisher’s Exact Test,
α=0.05), nor that at the second insertion step (P-value=0.49, Fisher’s Exact Test, α=0.05).
Therefore, Pol iota did not have any effect on bypassing the Pt-GG lesion.
In the high-throughput TLS assay, I also could not detect the effect of Pol iota between
the MEF POLI(+/+) cell line and the MEF POLI(-/-) cell line.
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In the traditional TLS assay, while Pol eta inserted the correct C at the first insertion step,
Pol iota had no effect. In the high-throughput assay, I could not detect the biological
function of Pol iota nor that of Pol eta by comparing their wild type cell line to their
respective isogenic single knockout cell line. In Section 3.11, I detected effects of
knocking out both the POLI gene and the POLH gene using double- and triple-knockout
MEF cell lines (Figure 15).

3.10 Rev3L and Rev1 bypassed Pt-GG in mammalian cells
Rev3L is the catalytic subunit of Pol zeta, a B-family DNA polymerase. It has been
shown that Rev3L and Rev1 functionally interact in translesion synthesis with Rev1
acting as a scaffold protein to recruit Rev3L via an interaction with Rev7, the accessory
subunit of Pol zeta (Murakumo et al., 2001; Kikuchi et al., 2012). Knocking down
REV3L or REV1 sensitizes mammalian cells to cisplatin (Doles et al., 2010; Xie et al.,
2010). To determine if Rev3L and Rev1 played any roles in the bypass of the Pt-GG
lesion in mammalian cells, I used the high-throughput TLS assay.
The high-throughput TLS assay showed that Rev3L and Rev1 bypassed Pt-GG in vivo by
producing mutations. Lesion gap plasmids containing a Pt-GG lesion were co-transfected
with control gap plasmids without the lesion into pairs of isogenic MEF cell lines. To
deduce the cellular function of Rev3L, the frequencies of CC->AC, CC->TC, CC->AA
and CC->AT substitutions across from the Pt-GG lesion were compared between the
3(+)6 REV3L(+/lox) Cre cell line and each of the 4(-)5 and 4(-)11 cell lines with the
genotype REV3L(-/lox) Cre, and between the B2 REV3L(+/+) P53(-/-) cell line and each
of the B4(-)9 and B4(-)18 cell lines with the genotype REV3L(-/-) P53(-/-). To deduce the
function of Rev1, mutation frequencies of Pt-GG of the MEF REV1(+/+) cell line were
compared to those of the MEF REV1(-/-) cell line. Nine transfection experiments were set
up for each cell line.
Gap regions of the control plasmids and lesion plasmids recovered from mammalian cells
were amplified in separate PCR reactions and sequenced by Next Generation Sequencing.
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In data analysis, the within-sample ratios AC/CC, TC/CC, AT/CC and AA/CC were
taken and then log 2 transformed. Each of the ratios log2(AC/CC), log2(TC/CC),
log2(AT/CC), log2(AA/CC) of a cell line (with nine biological replicates) was compared
to that of the other cell line (also with nine biological replicates) by the Wilcoxon Rank
Sum Test. Wilcox Rank Sum Test evaluates the likelihood that the medians of the ratios
from the two cell lines are from two different populations. P-values calculated by Wilcox
Rank Sum Tests were adjusted by the Benjamini-Hochberg method to control the false
discovery rate of the study. Where the adjusted P-value was less than 0.05, meaning that
the probability of falsely detecting an effect for the study is 5% at most, the difference
between the cell lines was deemed statistically significant and the effect size (Cohen’s d)
and its 95% confidence interval were calculated. An effect size of 0.6 or greater is
considered large by convention.
The Pt-GG study and bypass of the lesion by five translesion DNA polymerases took up
86% of the total sequencing capacity. Numbers of reads (for the control and for the lesion
plasmids) obtained for every transfection experiment are shown in Figure 13.
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Figure 13 Reads obtained for every transfection experiment in the Pt-GG study
Number of reads for the control plasmid and number of reads for the lesion plasmid for
every transfection experiment in the Pt-GG study (see Appendix I for raw data). The
control plasmids and the lesion plasmids of a transfection experiment were amplified in
separate PCR reactions for a total of 55 cycles and their reads were sorted by barcodes.
There are 192 transfection experiments, including nine biological replicates for each of
the twenty cell lines listed in Table 4 and positive and negative control reactions done in
triplicates. Positive control PCR reactions used the control plasmid without the gap or the
lesion plasmid without the lesion and without the gap as DNA template. There are two
types of negative control experiments: in the first type, no transfection reagent was
added, so gap plasmids did not enter into mammalian cells. The purpose of this negative
control experiment is to check that the gap plasmids were effectively removed by alkaline
lysis. In the second type of negative control, no DNA template was added in the PCR
reactions.

The mutation frequency of Pt-GG was in the order of 10-3 and was similar to that of a
regular GG dinucleotides. Rev3L and Rev1 had no effects on bypassing GG in the
control plasmids but produced mutations opposite to Pt-GG in the lesion plasmids where
50% of the mutations were CC->AC substitutions. The effect of Rev3L was validated in
more than one pair of cell lines. Knocking out REV3L or REV1 resulted in less frequent
CC->AC substitutions (Figure 14). In addition to CC->AC substitutions, knocking out
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REV3L in a P53 null genetic background resulted in less frequent CC->TC substitutions
(Table 9). The same results were obtained from NGS data sequenced in the reverse
direction (Appendix B).

Figure 14

Knocking out REV3L or REV1 resulted in less frequent CC->AC

substitutions across from Pt-GG
Knocking out the REV3L gene conditionally or in a P53 null genetic background resulted
in less frequent CC->AC substitutions across from Pt-GG; each result was confirmed in
two pairs of isogenic cell lines. Knocking out the REV1 gene produced a similar effect as
knocking out the REV3L gene. Effect sizes and Benjamini Hochberg (BH) adjusted Pvalues are shown for the comparisons between isogenic cell lines.

Table 9 Knocking out REV3L resulted in less frequent substitutions of CC->TC
across from Pt-GG
Genotypes of cell lines compared
(N=9 groups)
REV3L(+/+) P53(-/-) versus REV3L(-/-) P53(-/-)
Nicknames: B2 versus B4(-)18

Adjusted
P-value
0.0018

Cohen’s 95% C. I.
d
2.28
0.88-3.67
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There is strong support for Rev3L functioning as a major DNA polymerase to bypass PtGG in mammalian cells. It has been reported that cell lines lacking a functional REV3L
gene are hypersensitive to cisplatin treatment (Zander and Bemark, 2004). A twopolymerase model based on protein-protein interaction studies suggested that the
complete bypass of Pt-GG requires Rev3L to act as an extender DNA polymerase,
preceded by another DNA polymerase inserting a nucleotide at the first insertion step.
Here I show that knocking out REV3L caused either A or T to be mis-incorporated at the
first insertion step to a Pt-GG lesion, hence Rev3L can function on its own to bypass the
lesion.
Knocking out REV1 produced a similar effect as knocking out REV3L. Rev1 may bypass
Pt-GG indirectly by acting as a scaffold protein to recruit Rev3L or other translesion
DNA polymerases. If REV1 and REV3L proteins require each other to function properly
in translesion synthesis, disrupting either the REV1 or the REV3L gene could entail a
completely different DNA polymerase to bypass Pt-GG. The ability of Rev1 to bypass PtGG directly has not been studied in vitro.

3.11 Each of Pol kappa and Pol eta associated with Pol iota in the
bypass of Pt-GG in vivo
To determine the effects of Pol kappa, Pol iota and Pol eta on the bypass of the Pt-GG
lesion, I used the high-throughput TLS assay. Although recently structural explanations
were provided for the correct bypass of Pt-GG at the first insertion step by Pol eta
(Ummat et al., 2012; Zhao et al., 2012), I did not find any effects of Pol eta, at least not
by itself, on bypassing the DNA lesion in vivo. My results show that Pol kappa, rather
than Pol eta bypassed Pt-GG and the bypass was error-prone (Figure 15).
To deduce the function of Pol kappa, isogenic cell lines with and without the POLK gene
were compared. The POLK wild type cell line was compared to the POLK(-/-) single
knockout cell line; the POLI(-/-) cell line was compared to the POLK(-/-) POLI(-/-)
double knockout cell line; the POLH(-/-) POLI(-/-) cell line (with functional POLK gene)
was compared to each of the POLH(-/-) POLI(-/-) POLK(-/-) triple knockout cell lines

51

2091 and 2095, respectively (Figure 15). Although in vitro studies have shown that Pol
kappa cannot bypass a Pt-GG adduct in DNA template (Gerlach et al., 2001), work done
by Vikash Jha in our lab showed that Pol kappa had some activities in bypassing the
lesion in vitro (unpublished data). The ability of Pol kappa to bypass Pt-GG was
functionally redundant to that of Pol iota, because the effect of knocking out Pol kappa
was only detected in the absence of Pol iota, and vice versa (Figure 15). Knocking out
Pol kappa and Pol iota together resulted in less frequent CC->AC and CC->AA
substitutions across from the lesion (Figure 15, Table 10).
Table 10

Knocking out POLK and POLI together resulted in less frequent

substitutions of CC->AA across from Pt-GG
Genotypes of cell lines compared
(N=9 groups)
POLK wild type vs. POLK(-/-) POLI(-/-) DKO
POLI wild type vs. POLK(-/-) POLI(-/-) DKO

Adjusted
P-value
0.038
0.0018

Cohen’s 95% C. I.
d
2.13
0.77-3.49
2.27
0.88-3.66
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Figure 15 Knocking out POLK in the absence of POLI or knocking out POLH in the
absence of POLI resulted in less frequent CC->AC substitutions across from Pt-GG
While the effect of Pol kappa could not be detected between the POLK(+/+) wild type
cell line and the POLK(-/-) single knockout cell line, knocking out the POLK gene in the
absence of the POLI gene or vice versa resulted in less frequent CC->AC substitutions.
Knocking out the POLK gene and the POLI gene together produced less frequent CC>AC substitutions. Knocking out the POLH gene and the POLI gene together also
resulted in less frequent CC->AC substitutions. The function of Pol iota was associated
with those of Pol kappa and Pol eta in the bypass of Pt-GG.

To deduce the function of Pol eta, isogenic MEF cell lines with and without the POLH
gene were compared. The POLH(+/+) cell line was compared to the POLH(-/-) single
knockout cell line and to the POLH(-/-) POLI(-/-) double knockout cell line, respectively.
The POLK(-/-) cell line (with functional POLH and POLI genes) was compared to each
of the POLK(-/-) POLI(-/-) POLH(-/-) triple knockout cell lines 2091 and 2095,
respectively. My result shows that Pol eta and Pol iota together bypassed Pt-GG and
made CC->AC and CC->AT substitutions (Figure 15, Table 11), suggesting that the two
DNA polymerases cooperated to bypass the Pt-GG lesion. It has been shown that
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localization of Pol iota to replication foci is largely dependent on Pol eta and that the Cterminal 224 amino acids of Pol iota are sufficient for binding to Pol eta (Kannouche et
al., 2003). It has also been reported that physical and functional interactions of Pol eta
and Pol iota are mediated by ubiquitin and are dependent on ubiquitination of either of
the DNA polymerases (McIntyre et al., 2013).
Table 11

Knocking out POLH and POLI together resulted in less frequent

substitutions of CC->AT across from Pt-GG
Genotypes of cell lines compared
(N=9 groups)
POLH wild type vs. POLH(-/-) POLI(-/-) DKO

Adjusted
P-value
0.038

Cohen’s 95% C. I.
d
1.85
0.56-3.14

Despite the low mutation rate of Pt-GG, which was similar to that of a regular GG
dinucleotides, several translesion DNA polymerases could be recruited, possibly via
different pathways to bypass the lesion in mammalian cells. I do not know yet which
DNA polymerase(s) correctly bypassed Pt-GG in the cell, but it would be interesting to
find out.
Since Pt-GG is implicated in blocking DNA replication (Vaisman et al., 2000; Chijiwa et
al., 2010; Zhao et al., 2012), I would like to determine the bypass efficiency of the DNA
lesion. In the next section, I present results of the traditional TLS assay, Q-PCR and the
high-throughput TLS assay for studying translesion synthesis efficiencies of Pt-GG and
8-oxo-G and in other words, measuring the blocking effects of the DNA lesions.

3.12 Pt-GG and 8-oxo-G had similar blocking effects to DNA
replication
In addition to mutagenesis, DNA lesions are replicated less efficiently than regular
nucleotides. The delay in replicating a DNA lesion relative to a normal nucleotide allows
recruitment of translesion DNA polymerases to bypass damaged DNA. I speculated that
the blocking effect of a DNA lesion is directly related to its size. Pt-GG is believed to be
highly blocking to DNA replication because it involves crosslinking of two adjacent
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purine bases (Vaisman et al., 2000; Chijiwa et al., 2010); by contrast, 8-oxo-G is believed
to be less obstructive to DNA replication. (Shibutani et al., 1991; Einolf and Guengerich,
2001; Avkin and Livneh, 2002; Markkanen et al., 2012) I hypothesized that Pt-GG has a
larger blocking effect than 8-oxo-G in vivo.
Studying the blocking effect of a DNA lesion is important because the difference in the
bypass efficiency of Pt-GG and 8-oxo-G could entail different mechanisms of recruiting
translesion DNA polymerases. The widespread presence of Pt-GG in patients who are
treated with cisplatin is thought to kill tumor cells by preventing DNA replication.
To investigate translesion synthesis efficiencies of 8-oxo-G and Pt-GG in mammalian
cells, I first used the traditional TLS assay and Q-PCR to study bypass efficiency of 8oxo-G in four DNA samples. There I found a discrepancy in the results of the two
methods (Table 12 and Table 13). Then I used Q-PCR to study the bypass efficiencies of
8-oxo-G and Pt-GG, respectively, in nine MEF cell lines and validated the results using
data of Next Generation Sequencing (Table 14 and Table 15).
In the traditional TLS assay, the translesion synthesis efficiency is estimated by taking
the ratio of the number of bacterial colonies arising on a kanamycin plate (selecting for
the lesion plasmids), to that arising on a chloramphenicol plate (selecting for the control
plasmids). Four DNA samples A, B, C, D extracted from the four cell lines MEF
POLI(+/+), MEF POLI(-/-), BL2 POLI(+/+), and BL2 POLI(-/-), respectively, were
transformed into CSH117 electrocompetent cells in triplicates.

Following each

transformation, undiluted cells were plated in triplicates on kanamycin plates and on
chloramphenicol plates, and the number of bacterial cells arising on the plates were
counted. The Kan/Cm ratio was calculated using average numbers of bacterial colonies
from the three kanamycin plates (Kan) and from the three chloramphenicol plates (Cm).
Results of the translesion synthesis efficiencies of 8-oxo-G measured from the four DNA
samples with the traditional TLS assay are shown in Table 12.
Using the same four DNA samples as above, I measured the number of copies of lesion
plasmids and that of the control plasmids by Q-PCR and then calculated the Kan/Cm
ratio for each DNA sample (Table 13). DNA standards and unknown samples were
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measured in replicates. Q-PCR reactions were set up using 2x EvaGreen qPCR Master
Mix and ran on the Eppendorf RealPlex Mastercycler instrument.

Table 12 Bypass efficiencies of 8-oxo-G estimated by the traditional TLS assay
Gap plasmids transfected into mammalian cells were repaired and then recovered by the
Alkaline Lysis method. The DNA was transformed, in three independently
transformation experiments into bacteria (CSH117 strain). In the table are numbers of
bacterial colonies arising on three kanamycin (Kan) plates and on three chloramphenicol
(Cm) plates when undiluted bacterial cells from each transformation experiment were
spread. The bypass efficiency of 8-oxo-G (Kan/Cm) is calculated as the ratio of the
average number of bacterial colonies on the Kan plates to that on the Cm plates.

Plate
The
1st Kan
transformation Cm
experiment
Kan/Cm

The
2nd Kan
transformation Cm
experiment
Kan/Cm

The
3rd Kan
transformation Cm
experiment
Kan/Cm

A

B

C

D

3LG188.1

3LG188.2

3LG102.5

MEF POLI(+/+)

MEF POLI(-/-)

BL2 POLI(+/+)

3LG102.6
BL2 POLI(-/-)

22, 32, 24

26, 28, 24

18, 20, 18

12, 26, 18

1.42

1.37

54, 70, 55

52, 69, 171

26, 24, 20

10, 5, 8

25, 24, 38

30, 22, 24

24, 12, 28

4, 5, 8

2.07

2.34

1.09

1.33

30, 43, 29

79, 86, 86

49, 36, 35

25, 37, 23

28, 35, 27

62, 53, 63

41, 24, 49

19, 26, 19

1.13

1.4

1.05

1.32
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Table 13 Bypass efficiencies of 8-oxo-G of the same DNA samples as in Table 12
measured by Q-PCR
Gap plasmids transfected into mammalian cells were repaired and then recovered by the
Alkaline Lysis method that effectively eliminated any unrepaired plasmids. From the
DNA sample, the number of copies of control plasmids and the number of copies of
lesion plasmids were measured by quantitative PCR using standard curves. Ct is the cycle
threshold number set above the background in a Q-PCR reaction; it is used to determine
the concentration or the copy number of the plasmids.
A

B

C

D

3LG188.1

3LG188.2

3LG102.5

3LG102.6

MEF POLI(+/+)

MEF POLI(-/-)

BL2 POLI(+/+)

BL2 POLI(-/-)

replicates

1

2

1

2

1

2

1

2

Ct value, p-Kan

10.74

10.54

14.95

15.19

11.59

11.6

11.75

11.72

Ct value, p-Cm

11.93

11.55

17.46

17.56

12.96

12.86

12.65

13

Copy no. p-Kan

4.55E+8

5.34E+8

1.54E+7

1.27E+7

2.30E+8

2.28E+8

2.02E+8

2.07E+8

Copy no. p-Cm

3.57E+9

4.59E+9

9.39E+7

8.79E+7

1.81E+9

1.94E+9

2.22E+9

1.77E+9

Kan/Cm ratio

0.13

0.12

0.16

0.14

0.13

0.12

0.09

0.12

The bypass efficiencies of 8-oxo-G measured by the traditional TLS assay exceed one
and show large variations among repeat transformation experiments (
Table 12). Given that the lesion gap plasmids and the control gap plasmids were cotransfected in equal molar amounts, a Kan/Cm ratio greater than one would indicate that
the lesion plasmids were repaired more efficiently than the control plasmids and that 8oxo-G was replicated more rapidly than a regular G—a result contrary to my expectation.
Using Q-PCR, however, I found that for the same DNA samples the bypass efficiencies
of 8-oxo-G were around 0.12 (Table 13), which indicates that for every ten control gap
plasmids that were filled, one lesion gap plasmid was repaired, or that 8-oxo-G was
bypassed at about one tenth the rate of a regular nucleotide in cells. Results of the Q-PCR
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experiments are more reproducible. I believe Q-PCR is a more reliable and accurate
method than the traditional TLS assay in estimating a DNA lesion’s bypass efficiency.
Next, I used Q-PCR to determine the translesion synthesis efficiencies of 8-oxo-G and PtGG, respectively, from nine MEF cell lines, and validated the results using the highthroughput data. I wanted to know how the bypass efficiencies of 8-oxo-G and Pt-GG
differ. Furthermore, I asked if the translesion synthesis efficiencies of the lesions were
influenced by knocking out one, two or three of the DNA polymerase genes POLI, POLK
and POLH. If Pol iota or Pol kappa or Pol eta was the only DNA polymerase in cells able
to bypass either of the DNA lesion, inactivating the DNA polymerase should greatly
reduce the bypass efficiency for that DNA lesion.
Q-PCR reactions were set up on a 384-well plate using Syber Select Master Mix and ran
in the ViiA7 instrument as described in Methods. The four DNA samples measured
previously were not used in this experiment. For each cell line, samples of three
transfection experiments were measured (Table 14) and three technical replicates were
set up to measure each sample. Translesion synthesis efficiencies of the same samples in
Table 14 were also determined and validated using results of the high-throughput TLS
assay (Table 15), based on the ratio of the number of reads obtained for the lesion
plasmids to that obtained for the control plasmids for a given transfection experiment
(Table 15).
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Table 14 Bypass efficiencies of 8-oxo-G and Pt-GG in nine MEF cell lines measured
by Q-PCR
Each Kan/Cm ratio in the table is the number of copies of lesion plasmids to that of
control plasmids for a transfection experiment and the number shown is the average of
three technical replicates.
8-oxo-G
Kan/Cm ratios of
Genotypes of MEF biological replicates
cell lines
1
2
3

Pt-GG
three Kan/Cm ratios of
biological replicates
1
2
3

three

POLI wild type

0.68

0.62

0.9

0.8

0.7

0.67

POLI(-/-)

2.34

0.9

0.83

0.45

0.68

0.63

POLH wild type

0.81

0.65

0.65

0.57

0.53

0.51

POLH(-/-)

0.53

0.67

0.68

0.56

0.53

0.49

POLK wild type

0.52

0.46

0.50

0.72

0.61

0.57

POLK(-/-)

0.65

1.20

0.51

0.68

0.85

0.69

POLH/I DKO

0.54

0.71

0.60

0.56

0.56

0.64

POLK/I DKO

0.58

0.59

0.54

0.57

0.53

0.68

2091 POLH/K/I TKO

0.74

0.83

0.72

1.20

0.86

0.85
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Table 15 Bypass efficiencies of 8-oxo-G and Pt-GG of the same samples as in Table
14 determined from the NGS data
Each number is the ratio of the number of reads obtained for the lesion plasmids to that
obtained for the control plasmids for a transfection experiment.
8-oxo-G
Kan/Cm ratios of
Genotypes of MEF biological replicates
cell lines
1
2
3

Pt-GG
three Kan/Cm ratios of
biological replicates
1
2
3

three

POLI wild type

0.54

0.61

0.61

1.09

0.95

0.90

POLI(-/-)

0.75

0.59

0.55

0.54

0.90

0.79

POLH wild type

0.67

0.63

0.59

0.74

0.80

0.83

POLH(-/-)

0.58

0.59

0.57

0.74

0.91

0.82

POLK wild type

0.47

0.47

0.42

1.83

1.61

1.73

POLK(-/-)

0.59

0.57

0.65

1.37

1.02

1.21

POLH/I DKO

0.56

0.59

0.55

0.60

0.11

0.61

POLK/I DKO

0.55

0.59

0.60

0.69

0.66

0.67

2091 POLH/K/I TKO

0.60

0.65

0.66

0.60

0.80

0.52

Translesion synthesis efficiencies of 8-oxo-G and Pt-GG determined by Q-PCR and by
the high-throughput TLS assay are in good agreement (Table 14 and Table 15) despite a
few outliers with values greater than 1. All the data considered there is no statistically
significant difference between the bypass efficiencies of 8-oxo-G and Pt-GG; the average
Kan/Cm ratio of either of the two DNA lesions is about 0.6. Knocking out the genes
POLI, POLK and POLH did not have any effects on the bypass efficiency of 8-oxo-G or
the bypass efficiency of Pt-GG.
Even though Pt-GG has been shown to be highly blocking to DNA replication under
well-defined in vitro conditions, it was not the case in vivo. My results show that the
blocking effect of Pt-GG was the same as that of 8-oxo-G in mammalian cells. It can be
reasoned that DNA polymerases accommodated a single base of Pt-GG rather than the
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cross-linked dimer in catalysis. Since the genotypes of the cell lines did not have any
effects on the TLS efficiencies of either of the two DNA lesions, the functions of Pol iota,
Pol kappa and Pol eta were not obligatory for the bypass of 8-oxo-G or Pt-GG in
mammalian cells. Other DNA polymerases could fill the gap plasmids and bypass the
DNA lesions.
Even though Pt-GG presents itself as a major roadblock for certain DNA polymerases in
vitro, cells have capabilities to bypass this lesion efficiently because multiple DNA
polymerases could carry out this function in vivo. Pt-GG hindered DNA replication, but
surprisingly, its blocking effect was comparable to that of 8-oxo-G and was not as severe
as previously implicated. This suggests that the presence of Pt-GG in DNA is not a major
contributing factor to the anti-tumor property of cisplatin. On the other hand, 8-oxo-G
was replicated less efficiently compared to a regular G nucleotide and the lesion’s
blocking effect was greater than previously considered. The finding that 8-oxo-G and PtGG lesions were bypassed with similar efficiencies in vivo was not expected judging by
the relative size of the two lesions.
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Chapter 4
4

Discussions
4.1

Traditional TLS assay and high-throughput TLS assay
revealed totally different results

Mutation frequencies of 8-oxo-G and Pt-GG were 37% (64/174 sequences) and 22%
(25/110 sequences), respectively, in MEF cells estimated by the traditional TLS assay,
and 91% (254,481/279,650 reads) and less than 1% (21,520/4,491,510 reads),
respectively, in MEF cells estimated by the high-throughput TLS assay. Whereas the
traditional TLS assay was inconclusive about the role of Pol iota in bypassing 8-oxo-G,
the high-throughput TLS assay showed that Pol iota did not have an effect. Whereas the
traditional TLS assay showed that Pol eta correctly bypassed Pt-GG in the first insertion
step and that Pol iota had no effect in bypassing the DNA lesion, the high-throughput
TLS assay showed that neither Pol eta nor Pol iota had any effects, but that Pol kappa
bypassed Pt-GG and the bypass was error-prone. Results of the traditional TLS assay
show that 8-oxo-G was replicated more efficiently than a regular G nucleotide, which is
contrary to my expectation. Results of the high-throughput TLS assay on the other hand,
show that the bypass efficiency of 8-oxo-G and that of Pt-GG were about 0.6 relative to
regular nucleotides measured by Q-PCR and Next Generation Sequencing. This means
that each of 8-oxo-G and Pt-GG was replicated at 0.6 times the rate of regular
nucleotides. I believe the differences in results between the traditional TLS assay and the
high-throughput TLS assay are due to the use of E. coli in the traditional TLS assay. The
high-throughput TLS assay is better able to capture mutations made inside mammalian
cells caused by DNA lesions.
The high-throughput TLS assay produced more consistent results across transfection
experiments than the traditional TLS assay. Next Generation Sequencing generated a
much larger sample size than the traditional TLS assay for each transfection experiment.
The traditional TLS assay revealed that the mutation frequency of 8-oxo-G was 33% in
both the MEF POLI(+/+) cell line (33/89 sequences) and the MEF POLI(-/-) cell line
(31/85 sequences), and was 18% in the BL2 POLI(+/+) cell line (17/93 sequences)and
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27% in the BL2 POLI(-/-) cell line (24/89 sequences). The high-throughput TLS assay
showed that the mutation frequency of 8-oxo-G was 91% in all four of the cell lines
where thousands of sequences were analyzed for each cell line. The difference in
mutation frequency of a DNA lesion was very subtle in the high-throughput TLS assay
across all the cell lines, less than 1% for sure. As a result, the high-throughput data must
be analyzed differently from the data of the traditional TLS assay. The high-throughput
data were treated as compositional and log-ratio analyses were used to detect differences
in mutation frequencies of a DNA lesion in pairs of isogenic cell lines.
The use of E. coli in the traditional TLS assay not only had impact on the mutation
frequencies of 8-oxo-G and Pt-GG, but also resulted in additional mutations arising in the
gap region close to the DNA lesion (Appendix C). These mutations were not observed in
the high-throughput TLS assay so they must have arisen in bacteria. In the highthroughput assay, a mutation was observed only where across from a DNA lesion.
Observations from the traditional TLS assay demonstrate that a damaged nucleotide in a
DNA sequence could, over the course of many rounds of DNA replications and cell
divisions in bacteria, cause mutations of its neighboring bases. Not realizing that
mutations in the traditional TLS assay result from multiple events, observations of
mutations caused by a DNA lesion in bacteria led to the development of a twopolymerase model for translesion synthesis. In this model, translesion synthesis is divided
into two steps, insertion to the lesion and extension with each step requiring a different
error-prone DNA polymerase, because mutations across from and next to a DNA lesion
were thought to be made by different error-prone DNA polymerases (Prakash and
Prakash, 2002; Friedberg et al., 2005; McCulloch and Kunkel, 2008; Shachar et al.,
2009). Results of the high-throughput TLS assay show that mutations that were not
directly opposite to DNA lesions did not result immediately from translesion synthesis,
thus calling into question the two-polymerase model.
Results of the high-throughput TLS assay are consistent with polymerase switching
whereby a translesion DNA polymerase is recruited to specifically insert a nucleotide
opposite to the lesion. The results are also consistent with having just one translesion
DNA polymerase filling the entire gap region, because the error rate of a translesion
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DNA polymerase is 10-2 to 10-4 and the gap region spans only 12 nucleotides. Therefore,
translesion DNA polymerases play important roles in synthesizing short gaps in DNA
repairs.

4.2

Several DNA polymerases can bypass 8-oxo-G and Pt-GG in
cells

We predicted that Pol iota is the only DNA polymerase to correctly bypass 8-oxo-G in
vivo, but found instead Pol eta carried this function in mammalian cells. Effects of Pol
iota were detected in the absence of Pol eta or Pol kappa; therefore, Pol iota together with
Pol eta and Pol iota together with Pol kappa bypassed 8-oxo-G correctly. In one of the
four pairs of REV3L cell lines, Rev3L was found to bypass 8-oxo-G correctly.
Rev3L, Rev1 and Pol kappa bypassed Pt-GG in an error-prone manner in mammalian
cells. The functions of Rev3L and Rev1 may be associated because Rev1 can act as a
scaffold protein to recruit Rev3L (Acharya et al., 2006; Hashimoto et al., 2012; Kikuchi
et al., 2012). The biological function of Pol kappa was redundant with that of Pol iota
because Pol kappa’s effect was detected only in the absence of Pol iota, and vice versa.
Among Pol kappa, Pol iota and Pol eta, Pol kappa was the major DNA polymerase to
bypass Pt-GG, and contrary to previous reports (Ummat et al., 2012; Zhao et al., 2012),
Pol eta did not have a major role in bypassing the Pt-GG lesion. It was also reported that
Pol eta could not carry out translesion synthesis of Pt-GG (Chijiwa et al., 2010), because
in the structural study Pol eta could not incorporate nucleotides at the second insertion
step of the DNA lesion.

4.3

Properties of 8-oxo-G and Pt-GG in mammalian cells

In the beginning of the study, I thought that Pt-GG but not 8-oxo-G blocks DNA
replication because Pt-GG is a more bulky DNA lesion. While previous studies show that
Pt-GG cannot be readily bypassed by many DNA polymerases in vitro (Vaisman et al.,
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2000; Chijiwa et al., 2010), my results show that Pt-GG was bypassed with the same
efficiency as 8-oxo-G in mammalian cells.
The mutation rate of 8-oxo-G (9.1x10-1) was two orders of magnitudes higher than that of
Pt-GG (4.7x10-3) in vivo. The large difference in mutation rate reflected the difference in
intrinsic mutagenic properties of the DNA lesions. Pt-GG is less prone to base misinsertions because DNA polymerases allow some flexibility in DNA backbone and are
able to traverse the slight bent introduced by the intrastrand cisplatin crosslink when
incorporating nucleotides to Pt-GG. For the 8-oxo-G lesion, an additional oxygen atom in
a guanine base alters its charge and therefore resulted in a high frequency of A misincorporation against 8-oxo-G. The large difference in mutation rate of the two DNA
lesions could also be due to different DNA repair mechanisms involved in removing the
DNA lesions. Perhaps the mechanism for removing Pt-GG lesions acted sooner than that
for 8-oxo-G lesions. While 8-oxo-G is largely removed by base excision repair pathway
through recognition of the lesion by the DNA glycosylase enzyme OGG1, Pt-GG is
largely removed by nucleotide excision pathway that recognizes the distortion in local
DNA structure caused by the DNA lesion. The basis for recognizing the 8-oxo-G lesion
relies less on DNA geometry and possibly, more on charge and that for recognizing the
Pt-GG lesion rests on deviation in its local DNA structure. This could entail different
mechanisms (recruitment of different protein ensembles), thus different timings at which
the lesions were repaired. Clearly, 8-oxo-G is the more harmful of the two DNA lesions.
The high incidence of transversion mutations arising from 8-oxo-G underlines the
importance of DNA repair to remove this lesion before DNA replication.
Pt-GG caused very few mutations: its mutation rate was only two times the background
error rate in the NGS study. All of Pol iota, Pol kappa, Pol eta, Rev1 and Rev3L were
error-prone to the lesion. I do not know which DNA polymerase(s) bypassed Pt-GG
correctly in vivo, but it would be important to find out, because inactivating those DNA
polymerases should reduce drug resistance to cisplatin in chemotherapy.
Then a question arises: what makes the cisplatin drug effective to kill cancerous cells
since Pt-GG, a major species of cisplatin-DNA adducts, did not block DNA replication
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more than 8-oxo-G, and 8-oxo-G is an abundant DNA lesion. I argue that cisplatin’s drug
effect does not depend on Pt-GG to block DNA replication, at least not by Pt-GG alone,
and the toxicity of cisplatin to tumor cells have other explanations (Cepeda et al., 2007;
Jung and Lippard, 2007). For one, it is conceivable that inter-strand cisplatin DNA
adducts would stall normal DNA replication. Also, cisplatin-DNA adducts attract binding
of the nonhistone High Mobility Group (HMG)-family of proteins that alter chromatin
structures (Rabik and Dolan, 2007); HMG proteins bound to Pt-GG lesions or other
cisplatin-DNA adducts could stall DNA replication (Rabik and Dolan, 2007). Cisplatin
also modifies amino acid residues of cytoplasmic and nuclear proteins (Woźniak and
Błasiak, 2002) and HMG proteins bound to cisplatin modified proteins could disrupt the
cell’s internal architecture (Woźniak and Błasiak, 2002).

4.4

Limitations on using cell lines as models in the highthroughput TLS assay to study protein functions

There are limitations on using mammalian cell lines with specific gene knockouts to
study functions of translesion DNA polymerases. First, even with the Next Generation
Sequencing technology that produces thousands of reads for each cell line, the biological
effect of a single gene is elusive because only subtle differences in mutation frequencies
could be detected between isogenic cell lines. Second, results of the high-throughput TLS
assay are indirect as I do not know which DNA polymerase(s) actually fill the gap
plasmids in cells. The best I could do is to acknowledge a probability that the translesion
DNA polymerase in question has taken action. I do not know if the proteins are expressed
in wild type cells, since I could not detect Pol iota, Pol eta and Pol kappa in Western
Blotting experiments using monoclonal primary antibodies (results not shown). Labs that
generated the knockout cell lines used in this project (Table 4) have confirmed the
genotypes of the cell lines by PCR and checked the expressions of the DNA polymerases
by Western Blotting. Third, I overloaded the cells or stressed the system with exogenous
DNA in transfection, which might cause the cells to not behave as they would under
normal physiological conditions. Forth, in analyzing the NGS data I made exhaustive
comparisons between cell lines to deduce the functions of translesion DNA polymerases.
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The many t-tests performed greatly increases the chance of committing Type 1 error—
detecting an effect for a translesion DNA polymerase when in fact it does not have any.
Type 1 error cannot be eliminated even with P-value adjustment: the Benjamini
Hochberg method was chosen because it is less conservative than the Bonferroni
correction. For all of these reasons, my findings on the biological functions of translesion
DNA polymerases in the high-throughput TLS assay are preliminary and would need to
be validated by other means, such as in vitro assays using purified proteins.

4.5

The high-throughput TLS assay generated new hypotheses for
further testing

The high-throughput TLS assay is a valuable tool for generating new hypotheses. From
my results, Pol eta had a major role in correctly bypassing 8-oxo-G in mammalian cells.
This finding is supported by other reports that study the kinetics (Haracska et al., 2000;
Washington et al., 2001), X-ray crystal structures (Silverstein et al., 2010), and genetics
(Rodriguez et al., 2013) of the yeast Pol eta in bypassing 8-oxo-G.
Rev3L bypassed Pt-GG in all four pairs of the REV3L cell lines analyzed (Figure 14).
This finding is supported by previous reports that showed that Rev3L confers chemoresistance to cisplatin (Wang et al., 2009) and REV3L-deficient cells are sensitive to
cisplatin (Sonoda et al., 2003; Zander and Bemark, 2004; Doles et al., 2010). Knocking
out REV1 produced a similar effect as knocking out REV3L. Rev1 bypassed Pt-GG, and
Rev1 may function on its own or recruit Rev3L to bypass the DNA lesion. Compared to
Pol eta and Pol iota, Pol kappa had a greater activity in bypassing Pt-GG in vivo. Pol
kappa’s biological function was detected in the absence of Pol iota, and vice versa,
suggesting their functions were either complementary or redundant. Pol eta and Pol iota
together bypassed Pt-GG, suggesting a link between the two proteins. The functions of
Pol kappa, Pol iota and Pol eta in cells were not mutually exclusive; they could bypass
the same type of DNA lesions such as Pt-GG and could potentially interact when carrying
out translesion synthesis in mammalian cells.
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4.6

Other applications of the high-throughput TLS assay

The high-throughput TLS assay is a very useful method to determine the mutation rate
and the mutation spectrum of a DNA lesion in mammalian cells. The assay can be
conveniently adapted to test many DNA lesions in a few cell lines to pinpoint those
lesions that have the most mutagenic effects for further study. Researchers can choose to
use different cell types and change the sequence of the gap region of double stranded gap
plasmids in their experiments.
The high-throughput TLS assay can also be used to study the long-term effect of a DNA
lesion. A time-series study can be carried out to monitor changes in the mutation
frequency of a DNA lesion and changes in the mutation spectrum of the gap region of the
double stranded gap plasmids over the course of hours or days in mammalian cells.

4.7

A problem with using E. coli in the traditional TLS assay

The traditional TLS assay is not a quantitative method to study mutations made by DNA
lesions precisely because the method uses E.coli. The mutation frequency of a DNA
lesion observed after bacterial cells have grown overnight does not reflect the mutation
frequency of the lesion at the time of bacterial transformation.
To reconcile the results obtained from the traditional TLS assay and those obtained from
the high-throughput TLS assay, we must understand the difference in dynamics of using
E. coli versus PCR to amplify DNA. In both cases, the number of DNA sequences
increases exponentially, but a PCR reaction is a more stable and predictable system than
the bacterial cell. DNA amplification in PCR reactions is only limited by the
concentration of DNA templates and the number of PCR cycles. The Phusion® High
Fidelity DNA polymerase used in PCR reaction is assumed to not make any mutations.
DNA amplification in E. coli on the other hand, is not constant and is under selective
pressure—reflected by the change in growth rate of bacteria that may have a qualitative
effect on producing additional mutations from the one caused by DNA lesion. The
mutation rate of a DNA lesion conveys an impression of a linear relationship between
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mutations and the number of nucleotides replicated. Accumulation of mutations in
bacteria, however, is nonlinear and is subject to influences of bacteria’s growth
conditions that change with environment. Mutations observed in bacteria due to a DNA
lesion are results of a series of events starting with translesion synthesis and those
observed in mammalian cells are results of translesion synthesis only. Difference in time
produced different observations of mutations that arise from a single DNA lesion.

4.8

Accumulation of mutation is related to the cell's growth
condition

My study stumbles upon seeing mutations at different times, from within one generation
in mammalian cells—as in a still photograph, to across many generations in bacterial
cells—as in a time-lapsed photograph. The high-throughput TLS assay captures
mutations caused by a DNA lesion in the short term—the time frame is seven hours in
cells that double every 24 hours. The traditional TLS assay captures mutations caused by
a DNA lesion in the long term—the time frame is 16 hours in bacterial cells that double
every 20 minutes. In the high-throughput assay, we saw only mutation directly opposite
to the DNA lesion; in the traditional assay, however, we saw accumulation of mutations
at positions adjacent to the DNA lesion (Appendix C). The difference in results of the
two methods suggests that the long-term effect of a DNA lesion is closely related to the
cell's growth condition, and that a single mutation caused by a DNA lesion can lead to
other mutations in the nearby DNA sequence under selective pressure of the cell.
Observations from the traditional TLS assay are outcomes from a series of events led by
translesion synthesis of a DNA lesion.

4.9

Significance of translesion synthesis in survival

The long-term effects of a DNA lesion in mammalian cells after they have divided many
times may come to resemble the mutation spectrums observed in bacteria, with increased
likelihood of mutations for nucleotides adjacent to the DNA lesion. This would be the
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case especially if the growth condition of mammalian cells is limiting, such as under cell
culture environment.
In bacteria, a DNA lesion may have long been removed from DNA sequence as cells
continue to divide, but the effect of the DNA lesion, such as mutations resulting
immediately from the lesion can quickly lead to other changes in its surrounding
nucleotides. Cells have DNA repairs and other mechanisms to maintain the genome's
equilibrium so mutations cannot increase uncontrollably without qualitative changes in
the cell.
Cultured mammalian cells share the same growth dynamic as cultured bacterial cells, but
an important distinction is that mammalian cells divide every 24 hours instead of every
20 minutes so mutations in mammalian cells accumulate much more slowly. Mammalian
cells have more stable dynamics than bacterial cells due to their slower growth rates. This
implies that properties of mammalian cells change less than those of bacteria in the long
term and that mammalian cells can better resist changes to DNA sequence arising from a
DNA lesion. To further explain, it would be much harder for translesion synthesis to
cause mutations in nucleotides adjacent to DNA lesions in mammalian cells unless there
are also qualitative changes that speed up the cells’ growth rates. The longer time it takes
for mammalian cells to divide also leaves more chance for DNA repairs to remove a
DNA lesion before it is replicated. I argue that mutations resulting from DNA lesions
observed in bacteria forecast those that will be seen in malignantly transformed
mammalian cells with uncontrolled growth rate.
Studying translesion synthesis is looking at a very fundamental level how mutations arise
spontaneously in response to the environment. Accumulation of mutation is closely
linked to the cell's growth condition. While the high-throughput TLS assay is useful for
determining the mutation frequency and the mutation spectrum of a DNA lesion resulting
immediately from translesion synthesis in the mammalian cell, the traditional TLS assay
is useful for determining the long-term effect of the lesion in causing additional changes
to a DNA sequence.
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The genome is constantly under pressure from DNA lesions and translesion synthesis to
change its information content. There is an element of chance in where changes in DNA
sequences would occur. Though translesion synthesis causes subtle variations in the
genome and is thus easily dismissed, small changes in initial conditions can have farreaching consequences. DNA lesions and translesion synthesis are potent driving forces
of evolution, and similar to Lorenz's butterfly effect (Lorenz, E.N., 1972) small
perturbations occurring by chance in the sequence of the genome can, over a long time,
have a large effect in determining the cell’s fate.
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Appendix A Effects of translesion DNA polymerases in the 8oxo-G study
Table A-1

Findings from the control plasmids about the frequency of C->A

substitution across from a regular G nucleotide
Analyzed from reads sequenced in
the FORWARD direction
Genotypes of the MEF
cell lines compared
(N= 9 groups)

Analyzed from reads sequenced in
the REVERSE direction

Adj.
P-value

Cohen’s
d

95% C. I.

Adj.
P-value

Cohen’s
d

95% C. I.

POLI(-/-) versus
POLK(-/-) POLI(-/-) DKO

0.0029

-2.46

-3.9 to -1.02

0.027

-1.6

-2.83 to -0.36

POLK wild type versus
POLK(-/-) POLI(-/-) DKO

0.0024

-2.11

-3.47 to -0.76

0.0015

-21.32

-29.86
12.78

POLK(-/-) versus
POLK(-/-) POLI(-/-) DKO

0.0024

-2.59

-4.06 to -1.11

0.0015

-3.15

-4.79 to -1.51

POLK(-/-) versus
POLI/H/K TKO

2091

0.0143

-2.34

-3.75 to -0.93

0.0015

-2.96

-4.54 to -1.37

POLK(-/-) versus
POLI/H/K TKO

2095

0.023

-1.97

-3.3 to -0.65

0.0054

-2.36

-3.78 to -0.94

Table A-2

to

-

Findings from the lesion plasmids about the frequency of C->A

substitution across from 8-oxo-G
Analyzed from reads sequenced in
the FORWARD direction
Genotypes of the MEF
cell lines compared
(N=9 groups)

Analyzed from reads sequenced in
the REVERSE direction

Adj.
P-value

Cohen’s
d

95% C. I.

Adj.
P-value

Cohen’s
d

95% C. I.

0.023

-2.05

-3.38 to -0.71

0.015

-1.87

-3.16 to -0.57

POLH wild type versus
POLH(-/-)

0.0024

-2.97

-4.56 to -1.39

0.0026

-3.03

-4.63 to -1.42

POLH wild type versus
POLH(-/-) POLI(-/-) DKO

0.023

-2.16

-3.53 to -0.80

0.027

-2.07

-3.42 to -0.73

REV3L(+/+) P53(-/-) vs.
REV3L(-/-) P53(-/-)
Nick name:
B2 vs. B4(-)18
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Appendix B Effects of translesion DNA polymerases in the PtGG study
Translesion DNA polymerases did not make any mutations in the control plasmids.
Table B-1 Effects of translesion DNA polymerases on causing CC->AC substitution
across from Pt-GG
Analyzed from reads sequenced in
the FORWARD direction

Analyzed from reads sequenced in
the REVERSE direction

Genotypes of the MEF
cell lines compared
(N=9 groups)

Adj.
P-value

Cohen’s
d

95% C. I.

Adj.
P-value

Cohen’s
d

95% C. I.

REV1 wild
REV1(-/-)

0.0024

3.17

1.53-4.82

0.0041

3.22

1.56-4.88

0.0018

4.65

2.52-6.79

0.0041

4.86

2.66-7.06

0.0018

5.45

3.04-7.87

0.0041

5.12

2.82-7.42

0.015

2.17

0.81-3.54

0.037

1.79

0.51-3.06

0.0018

3.49

1.75-5.24

0.0041

2.92

1.35-4.49

POLI wild type vs.
POLK(-/-) POLI(-/-) DKO

0.0024

2.81

1.27-4.35

0.0097

2.64

1.15-4.13

POLI(-/-) vs.
POLK(-/-) POLI(-/-) DKO

0.006

2.49

1.04-3.94

0.016

2.45

1.01-3.9

0.029

1.86

0.57-3.15

0.042

1.97

0.65-3.28

0.0024

3.08

1.46-4.69

0.0041

3.31

1.62-5.0

type

vs.

REV3L(+/+) vs.
REV3L(-/Δ)
Nickname: 3(+)6 vs. 4(-)5
REV3L(+/+) vs.
REV3L(-/Δ)
Nickname:
3(+)6 vs. 4(-)11
REV3L(+/+) P53(-/-) vs.
REV3L(-/-) P53(-/-)
Nick name:
B2 vs. B4(-)18
REV3L(+/+) P53(-/-) vs.
REV3L(-/-) P53(-/-)
Nick name:
B2 vs. B4(-)18

POLI(-/-) vs.
2091 POLI(-/-) POLK(-/-)
POLH(-/-) TKO
POLI(-/-) vs.
2095 POLI(-/-) POLK(-/-)
POLH(-/-) TKO
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Table B- continues
Genotypes of the MEF
cell lines compared (N=9
groups)
POLH wild type vs.
POLH(-/-) POLI(-/-) DKO

Analyzed from reads sequenced in
the FORWARD direction

Analyzed from reads sequenced in
the REVERSE direction

Adj.
P-value

Cohen’s
d

95% C. I.

Adj.
P-value

Cohen’s
d

95% C. I.

0.038

1.7

0.44-2.95

0.049

1.76

0.49-3.03

0.0024

2.32

0.92-3.73

0.0041

2.36

0.95-3.78

0.0018

3.48

1.74-5.22

0.0041

3.59

1.81-5.37

POLK wild type vs.
POLK(-/-) POLI(-/-) DKO

0.0024

2.95

1.37-4.54

0.0041

2.96

1.37-4.54

POLK(-/-) vs.
POLK(-/-) POLI(-/-) DKO

0.01

2.28

0.88-3.67

0.042

1.96

0.64-3.28

0.004

2.98

1.39-4.57

0.0041

3.93

2.04-5.81

0.022

1.71

0.45-2.96

0.06

1.48

0.27-2.69

0.0024

3.17

1.52-4.81

0.0041

2.86

1.31-4.42

POLH(-/-) vs.
2091 POLI(-/-) POLK(-/-)
POLH(-/-) TKO
POLH(-/-) vs.
2095 POLI(-/-) POLK(-/-)
POLH(-/-) TKO

POLK(-/-) vs.
2095 POLI(-/-) POLK(-/-)
POLH(-/-) TKO
POLH(-/-) POLI(-/-) DKO
vs.
2091 POLI(-/-) POLK(-/-)
POLH(-/-) TKO
POLH(-/-) POLI(-/-) DKO
vs.
2095 POLI(-/-) POLK(-/-)
POLH(-/-) TKO

Table B-2 Effect of Rev3L on causing CC->TC substitution across from Pt-GG
Analyzed from reads sequenced in
the FORWARD direction
Genotypes of the MEF
cell lines compared
(N=9 groups)
REV3L(+/+) P53(-/-) vs.
REV3L(-/-) P53(-/-)
Nick name:
B2 vs. B4(-)18

Analyzed from reads sequenced in
the REVERSE direction

Adj.
P-value

Cohen’s
d

95% C. I.

Adj.
P-value

Cohen’s
d

95% C. I.

0.0018

2.28

0.88-3.67

0.049

1.64

0.4-2.89
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Table B-3 Effect of knocking out both Pol kappa and Pol iota on causing CC->AA
substitution across Pt-GG
Analyzed from reads sequenced in
the FORWARD direction

Analyzed from reads sequenced in
the REVERSE direction

Genotypes of the MEF
cell lines compared
(N=9 groups)

Adj.
P-value

Cohen’s
d

95% C. I.

Adj.
P-value

Cohen’s
d

95% C. I.

POLK wild type vs.
POLK(-/-) POLI(-/-) DKO

0.038

2.13

0.77-3.49

0.042

2.17

0.8-3.53

POLI wild type vs.
POLK(-/-) POLI(-/-) DKO

0.0018

2.27

0.88-3.66

0.0041

2.3

0.9-3.71

Table B-4 Effect of knocking out Pol eta and Pol iota together on causing CC->AT
substitution
Analyzed from reads sequenced in
the FORWARD direction
Genotypes of the MEF
cell lines compared
(N=9 groups)
POLH wild type vs.
POLH(-/-) POLI(-/-) DKO

Analyzed from reads sequenced in
the REVERSE direction

Adj.
P-value

Cohen’s
d

95% C. I.

Adj.
P-value

Cohen’s
d

95% C. I.

0.038

1.85

0.56-3.14

0.042

1.97

0.65-3.28
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Appendix C Mutations arising in the gap region of lesion gap
plasmids from the traditional TLS assay

For the 8-oxo-G lesion

Figure C-1 Mutations in the gap regions of 8-oxo-G lesion plasmids from a pair of
MEF cell lines
89 sequences were analyzed for the MEF POLI(+/+) cell line and 85 sequences were
analyzed for the MEF POLI(-/-) cell line. The gap sequence is flanked by two dashes.
The direction of gap-filling is from left to right or 5’ to 3’ of the synthesized strand. The
‘C’ with the highest mutation rate is opposite to 8-oxo-G.
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Figure C-2 Mutations in the gap regions of 8-oxo-G lesion plasmid from a pair of
BL2 cell lines
93 sequences were analyzed for the BL2 POLI(+/+) cell line and 89 sequences were
analyzed for the BL2 POLI(-/-) cell line. The gap sequence is flanked by two dashes. The
direction of gap-filling is from left to right or 5’ to 3’ of the synthesized strand. The ‘C’
with the highest mutation rate is opposite to 8-oxo-G.

Table C-1 Numbers of reads with mutations in the gap region of 8-oxo-G lesion
plasmids in a pair of MEF cell lines for the POLI gene and in a pair of BL2 cell lines
for the POLI gene. The “C” colored in red is across from the 8-oxo-G lesion. The 12nucleotide gap region is highlighted in yellow.
Sequence context for the 8-oxo-G study
C C A G G T A G G A C G C A T G C C G

Cell line

Total
reads

MEF
POLI WT
MEF
POLI(-/-)
BL2
POLI WT
BL2
POLI(-/-)

89

1

1

85

1

1

2 1

33 4
31

G

A A T

1 2
1

1

1

93

3

17 4

4 8

4

89

6 1

24 2

7 9

10

4
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For the Pt-GG lesion

Figure C-3 Mutations in the gap regions of Pt-GG lesion plasmids from a pair of
MEF cell lines for studying the effect of Pol iota
29 sequences for the MEF POLI(+/+) cell line and 24 sequences were analyzed for the
POLI(-/-) cell line. The gap sequence is flanked by two dashes. The direction of gapfilling is from left to right of the given sequence or 5’ to 3’ of the synthesized strand. C1
denotes the first G of Pt-GG bypassed by a DNA polymerase. C2 denotes the second G of
Pt-GG bypassed.

89

Figure C-4 Mutations in the gap region of Pt-GG lesion plasmids for a pair of MEF
cell lines for studying the effect of Pol iota.
29 sequences were analyzed for the MEF POLH(+/+) cell line and 28 sequences were
analyzed for the MEF POLH(-/-) cell line. The gap sequence is flanked by two dashes.
The direction of gap-filling is from left to right of the given sequence or 5’ to 3’ of the
synthesized strand. C1 denotes the first G of Pt-GG bypassed by a DNA polymerase. C2
denotes the second G of Pt-GG bypassed.

Table C-2 Numbers of reads with mutations in the gap region of Pt-GG lesion
plasmids in a pair of MEF cell lines for the POLI gene and in a pair of MEF cell
lines for the POLH gene. The “CC” colored in red is across from the Pt-GG lesion
with C1 denoting the first insertion step and C2 denoting the second insertion step to
the lesion. The 12 nucleotide gap region is highlighted in yellow.
Sequence context for the Pt-GG study
C C A G G G C1

Cell line

Total
reads

MEF
POLI WT
MEF
POLI (-/-)
MEF
POLH WT
MEF
POLH(-/-)

29

5

24

4

29
28

1

C2

A G A G G A A G C C G G A A T

2

4

1

1 2

1
1

1 2

2

1 2

1 1 8

2

2 2 1 1

1

1

90

Figure C-5 Mutation spectrums of the gap region of the Pt-GG lesion plasmids in a
pair of MEF cell lines for the POLI gene.
C1 and C2 denote the first and the second insertion step to the Pt-GG lesion. The gap
region of the lesion plasmid is highlighted in yellow. Each symbol above and below the
sequence shown in black is one observation of the mutation. Δ is deletion.

Figure C-6 Mutation spectrums of the gap region of the Pt-GG lesion plasmids in a
pair of MEF cell lines for the POLH gene.
C1 and C2 denote the first and the second insertion step to the Pt-GG lesion. The gap
region of the lesion plasmid is highlighted in yellow. Each symbol above and below the
sequence shown in black is one observation of the mutation. Δ is deletion. “AC” with the
same shading appears in the same sequence.
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Appendix D

Summary statistics of the MiSeq run

Table D-1 Summary statistics of the bi-directional 150 bp MiSeq run
Cycles Yield

Yield Perfect

Yield <=3 errors

% Aligned to PhiX

Read 1

150

2.8 gigabase

258.0 M

305.6M

10.95

Read 2

150

2.8 gigabase

231.8 M

293.7M

10.74

Total

300

5.6 gigabase

489.8 M

599.2 M

10.84

% Perfect
[num usable cycles]

Error
rate1 (%)

Intensity % Intensity
Cycle
Cycle 20

% >= Q30 2

Read 1

83.3 [149]

0.29

139

20.3

97.5

Read 2

76.3 [149]

0.48

120

18.0

96.0

Total

79.8

0.39

129

19.1

96.8

Note 1: The error rate was determined from a spiked-in PhiX control sample.
Note 2: Q score, also known as the Phred score was calculated as

, where P

is the error probability. A Q score of 30 means that there is one mistake per every
thousand nucleotides sequenced.

Figure D-1 Q score distributions of the MiSeq run
(A) By total reads. (B) By cycle. 96.8% of 5.5 gigabases have Q-scores equal to or
greater than 30.
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Appendix E

Isogenic cell lines compared when deducing
effects of translesion DNA polymerases on
bypassing 8-oxo-G or Pt-GG

Table E-1 A list of all the isogenic cell lines that were compared
Each cell line was used to set up nine transfection experiments or nine biological
replicates for the study of 8-oxo-G and Pt-GG lesions (Appendices G and J). For each
pair of cell lines, comparisons were made for the control plasmids and for the lesion
plasmids, respectively.
Effect of the
translesion DNA
polymerase(s)
being deduced

Genotypes of the cell lines compared
(each cell line has nine biological replicates)
Cell line
Cell line
(with the gene of the DNA
(deficient for the gene of the DNA
polymerase in question)
polymerase in question)

Pol iota

MEF POLI(+/+)
BL2 POLI(+/+)

MEF POL(-/-)
BL2 POLI(-/-)

Pol eta

MEF POLH(+/+)
MEF POLK(-/-) POLI(-/-)
MEF POLK(-/-) POLI(-/-)
MEF POLK(+/+)
MEF POLH(-/-) POLI(-/-)
MEF POLH(-/-) POLI(-/-)
MEF REV1(+/+)
MEF REV3L(+/+) P53(-/-)
or B2
MEF REV3L(+/+) P53(-/-)
or B2
MEF REV3L(+/lox) Cre
or 3(+)6
MEF REV3L(+/lox) Cre
or 3(+)6
MEF POLI(+/+)
MEF POLH(+/+)
MEF POLK(-/-)
MEF POLK(-/-)
MEF POLI(+/+)
MEF POLK(+/+)
MEF POLH(-/-)
MEF POLH(-/-)
MEF POLI(-/-)
MEF POLI(-/-)

MEF POLH(-/-)
2091 POLH(-/-) POLI(-/-) POLK(-/-)
2095 POLH(-/-) POLI(-/-) POLK(-/-)
MEF POLK(-/-)
2091 POLH(-/-) POLI(-/-) POLK(-/-)
2095 POLH(-/-) POLI(-/-) POLK(-/-)
MEF REV1(-/-)
MEF REV3L(-/-) P53(-/-)
or B4(-)9
MEF REV3L(-/-) P53(-/-)
or B4(-)18
MEF REV3L(-/lox) Cre
or 4(-)5
MEF REV3L(-/lox) Cre
or 4(-)11
MEF POLH(-/-) POLI(-/-)
MEF POLH(-/-) POLI(-/-)
2091 POLH(-/-) POLI(-/-) POLK(-/-)
2095 POLH(-/-) POLI(-/-) POLK(-/-)
MEF POLI(-/-) POLK(-/-)
MEF POLI(-/-) POLK(-/-)
2091 POLH(-/-) POLI(-/-) POLK(-/-)
2095 POLH(-/-) POLI(-/-) POLK(-/-)
2091 POLH(-/-) POLI(-/-) POLK(-/-)
2095 POLH(-/-) POLI(-/-) POLK(-/-)

Pol kappa

Rev1
Rev3

Pol iota and
Pol eta

Pol iota and
Pol kappa

Pol eta and
Pol kappa
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Appendix F No. of reads for DNA samples in the 8-oxo-G study
Transfection
Experiment

L1R1
L1R2
L1R3
L1R4
L1R5
L1R6
L1R7
L1R8
L1R9
L1R10
L1R11
L1R12
L1R13
L1R14
L1R15
L1R16
L1R17
L1R18
L1R19
L1R20
L1R21
L1R22
L1R23
L1R24

Transfection
Experiment

L3R1
L3R2
L3R3
L3R4
L3R5
L3R6
L3R7
L3R8
L3R9
L3R10
L3R11
L3R12
L3R13
L3R14
L3R15
L3R16

Total
Reads
5193
5523
4881
4938
4441
3722
4963
5413
4619
5820
4724
4256
5626
4451
4418
5236
6182
6631
9834
4456
4446
4543
4770
4439

Reads of
Control
Plasmids
3394
3485
3121
3161
2854
2382
3086
3392
2994
3490
3046
2735
3538
2822
2786
3332
3936
4137
6870
2820
2824
2932
3032
2811

Reads of
Lesion
Plasmids
1799
2038
1760
1777
1587
1340
1877
2021
1625
2330
1678
1521
2088
1629
1632
1904
2246
2494
2964
1636
1622
1611
1738
1628

Total
Reads
5280
5888
5577
5392
3687
3656
3592
4043
3740
3680
4387
3997
3974
4160
3915
4949

Reads of
Control
Plasmids
3366
3750
3500
3378
2361
2376
2314
2584
2543
2447
2992
2767
2667
2816
2403
3107

Reads of
Lesion
Plasmids
1914
2138
2077
2014
1326
1280
1278
1459
1197
1233
1395
1230
1307
1344
1512
1842

Reads of Reads of
Control
Lesion
Transfection Total
Reads Plasmids Plasmids
Experiment
L2R1
L2R2
L2R3
L2R4
L2R5
L2R6
L2R7
L2R8
L2R9
L2R10
L2R11
L2R12
L2R13
L2R14
L2R15
L2R16
L2R17
L2R18
L2R19
L2R20
L2R21
L2R22
L2R23
L2R24

4229
6307
6257
7310
10006
6933
6245
5365
4736
5485
4675
6966
7147
6961
4672
6050
7911
7432
5998
5008
8145
3894
7058
7232

2767
3982
3954
4648
6828
4394
3877
3370
3137
3504
3020
4298
4401
4332
2927
3809
5009
4782
3858
3221
5177
2625
4571
4569

1462
2325
2303
2662
3178
2539
2368
1995
1599
1981
1655
2668
2746
2629
1745
2241
2902
2650
2140
1787
2968
1269
2487
2663

Transfection
Experiment

Total
Reads
5567
5355
6128
6345
8271
7694
6325
7357
7111
6945
7669
8223
7401
8379
6419
6199

Reads of
Control
Plasmids
3442
3410
3795
4000
5220
5142
4051
4734
4623
4442
4920
5000
4459
5170
4017
3934

Reads of
Lesion
Plasmids
2125
1945
2333
2345
3051
2552
2274
2623
2488
2503
2749
3223
2942
3209
2402
2265

L4R1
L4R2
L4R3
L4R4
L4R5
L4R6
L4R7
L4R8
L4R9
L4R10
L4R11
L4R12
L4R13
L4R14
L4R15
L4R16
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Transfection
Experiment

L3R17
L3R18
L3R19
L3R20
L3R21
L3R22
L3R23
L3R24

Transfection
Experiment

L5R1
L5R2
L5R3
L5R4
L5R5
L5R6
L5R7
L5R8
L5R9
L5R10
L5R11
L5R12
L5R13
L5R14
L5R15
L5R16
L5R17
L5R18
L5R19
L5R20
L5R21
L5R22
L5R23
L5R24

Transfection
Experiment

L7R1
L7R2
L7R3
L7R4
L7R5
L7R6

Total
Reads
4010
4354
4610
4327
4031
3548
3821
3995

Reads of
Control
Plasmids
2522
2784
2958
2667
2547
2260
2378
2493

Reads of
Lesion
Plasmids
1488
1570
1652
1660
1484
1288
1443
1502

Total
Reads
7351
8251
7224
9021
7985
7033
9087
7589
8477
7374
10736
8844
9324
9991
5919
10110
7882
7006
7136
6720
9912
10269
9522
9009

Reads of
Control
Plasmids
4998
5682
4420
5513
4954
4497
5648
4745
5594
4816
7024
5689
5913
6476
3739
6401
6912
4505
4722
4344
6279
6376
5901
5856

Reads of
Lesion
Plasmids
2353
2569
2804
3508
3031
2536
3439
2844
2883
2558
3712
3155
3411
3515
2180
3709
970
2501
2414
2376
3633
3893
3621
3153

Total
Reads
12256
12487
11907
11752
11474
12120

Reads of
Control
Plasmids
7607
7794
7548
7557
7306
7797

Reads of
Lesion
Plasmids
4649
4693
4359
4195
4168
4323

Transfection
Experiment

L4R17
L4R18
L4R19
L4R20
L4R21
L4R22
L4R23
L4R24

Transfection
Experiment

L6R1
L6R2
L6R3
L6R4
L6R5
L6R6
L6R7
L6R8
L6R9
L6R10
L6R11
L6R12
L6R13
L6R14
L6R15
L6R16
L6R17
L6R18
L6R19
L6R20
L6R21
L6R22
L6R23
L6R24

Transfection
Experiment

L22R1
L22R2
L22R3
L22R4
L22R5
L22R6

Total
Reads
9094
4918
7306
6398
8753
7910
8483
6358

Reads of
Control
Plasmids
5758
3027
4534
4051
5605
5026
5463
4013

Reads of
Lesion
Plasmids
3336
1891
2772
2347
3148
2884
3020
2345

Total
Reads
10167
14701
10725
12411
12677
12833
13942
13615
12618
10513
14519
11808
11314
12280
14372
11779
13535
12023
13418
10946
15456
12554
11146
14447

Reads of
Control
Plasmids
6464
9212
6556
7734
7970
7822
8520
8249
8989
7405
10347
7271
6809
7137
9002
7439
8581
7359
8231
6750
9860
8020
7134
9048

Reads of
Lesion
Plasmids
3703
5489
4169
4677
4707
5011
5422
5366
3629
3108
4172
4537
4505
5143
5370
4340
4954
4664
5187
4196
5596
4534
4012
5399

Total
Reads
5312
6086
6395
5998
6670
6360

Reads of
Control
Plasmids
3437
3844
4053
3822
4260
3992

Reads of
Lesion
Plasmids
1875
2242
2342
2176
2410
2368
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L7R7
L7R8
L7R9
L7R10
L7R11
L7R12
L7R13
L7R14
L7R15
L7R16
L7R17
L7R18
L7R19
L7R20
L7R21
L7R22
L7R23
L7R24

Total
Reads
9487
13455
13440
11052
12217
12457
19743
13451
12535
12181
12666
15353
5311
5174
5684
5236
5091
6371

Reads of
Control
Plasmids
5913
8305
8535
6926
7663
7756
12271
8474
7849
7568
8063
9618
3378
3359
3694
3390
3320
4144

Reads of
Lesion
Plasmids
3574
5150
4905
4126
4554
4701
7472
4977
4686
4613
4603
5735
1933
1815
1990
1846
1771
2227

L22R7
L22R8
L22R9
L22R10
L22R11
L22R12
L22R13
L22R14
L22R15
L22R16
L22R17
L22R18
L22R19
L22R20
L22R21
L22R22
L22R23
L22R24

Total
Reads
6808
5962
6888
6118
6427
7113
7428
8403
1535
1700
4440
4322
4087
1419
1628
1415
1367
1602

Reads of
Control
Plasmids
4340
3874
4372
3948
4047
4330
4489
5204
1058
1191
3932
3841
3605
996
1120
991
960
1144

Reads of
Lesion
Plasmids
2468
2088
2516
2170
2380
2783
2939
3199
477
509
508
481
482
423
508
424
407
458

Note:
L22R15 and L22R16 are no DNA negative PCR controls whereby no DNA was added in
PCR reactions.
L22R17, L22R18 and L22R19 are positive PCR controls whereby intact double stranded
control plasmids were added in PCR reactions for determining experimental errors.
L22R20, L22R21 and L22R22 are negative controls for transfection whereby control gap
plasmids were added to MEF cells without transfection reagent.
L22R23 and L22R24 are negative controls for transfection whereby control gap plasmids
were added to BL2 cells without transfection reagent.
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Appendix G Cell lines used for transfection experiments in
the 8-oxo-G study
Cell line

Transfection experiments

MEF POLI(+/+)

L1R1 to L1R9

MEF POLI(-/-)

L1R10 to L1R18

BL2 POLI(+/+)

L1R19 to L1R24, L2R1 to L2R4

BL2 POLI(-/-)

L2R5 to L2R14

MEF POLH(+/+)

L2R15 to L2R23

MEF POLH(-/-)

L2R24, L3R1 to L3R8

MEF POLK(+/+)

L3R9 to L3R17

MEF POLK(-/-)

L3R18 to L3R24, L4R1, L4R2

MEF REV1(+/+)

L4R3 to L4R11

MEF REV1(-/-)

L4R12 to L4R20

MEF POLH(-/-) POLI(-/-)

L4R21 to L4R24, L5R1 to L5R5

MEF POLH(-/-) POLI(-/-) POLK(-/-), 2091

L5R6 to L5R14

MEF POLH(-/-) POLI(-/-) POLK(-/-), 2095

L5R15 to L5R23

MEF POLK(-/-) POLI(-/-), 2092

L5R24, L6R1 to L6R8

MEF REV3L(+/Δ), nickname: 3(+)6

L6R9 to L6R17

MEF REV3L(-/Δ), nickname: 4(-)5

L6R18 to L6R24, L7R1, L7R2

MEF REV3L(-/Δ), nickname: 4(-)11

L7R3 to L7R11

MEF REV3L(+/+), P53(-/-), nickname: B2

L7R12 to L7R20

MEF REV3L(+/+), P53(-/-), nickname: B4-9

L7R21 to L7R24, L22R1 to L22R5

MEF REV3L(+/+), P53(-/-), nickname: B4-18

L22R6 to L22R14
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Appendix H Mutation frequencies of control plasmids and
lesion plasmids in the 8-oxo-G study for each cell
line
Cell line
MEF POLI(+/+)
MEF POLI(-/-)
BL2 POLI(+/+)
BL2 POLI(-/-)
MEF POLH(+/+)
MEF POLH(-/-)
MEF POLK(+/+)
MEF POLK(-/-)
MEF POLH(-/-) POLI(-/-)
MEF POLH(-/-) POLI(-/-)
POLK(-/-), 2091
MEF POLH(-/-) POLI(-/-)
POLK(-/-), 2095
MEF POLK(-/-) POLI(-/-),
2092
MEF REV1(+/+)
MEF REV1(-/-)
MEF REV3L(+/Δ),
nickname: 3(+)6
MEF REV3L(-/Δ),
nickname: 4(-)5
MEF REV3L(-/Δ),
nickname: 4(-)11
MEF REV3L(+/+), P53(-/-),
nickname: B2
MEF REV3L(+/+), P53(-/-),
nickname: B4-9
MEF REV3L(+/+), P53(-/-),
nickname: B4-18

Average mutation
frequency across from a
regular G in control
plasmids (N=9 samples)
0.019265±0.003387
0.013826±0.002641
0.010293±0.007336
0.015254±0.005925
0.012623±0.004703
0.014634±0.006322
0.008282±0.003878
0.007575±0.005674
0.018589±0.005959
0.023589±0.004759

Average mutation
frequency across from an
8-oxo-G in lesion plasmids
(N=9 samples)
0.901709±0.020447
0.921682±0.025595
0.918242±0.043828
0.903451±0.031048
0.868926±0.029094
0.929683±0.010711
0.927235±0.024269
0.932431±0.014121
0.919158±0.016402
0.913149±0.004392

0.018639±0.002599

0.919177±0.015477

0.01898±0.006801

0.931155±0.009086

0.019328±0.005146
0.01682±0.00477
0.020843±0.003397

0.906739±0.011112
0.914846±0.011736
0.885401±0.020573

0.019108±0.001546

0.908886±0.009407

0.020931±0.004855

0.906337±0.007816

0.025063±0.008512

0.896716±0.020351

0.025855±0.01121

0.897937±0.03203

0.016891±0.005043

0.926601±0.011012
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Appendix I No. of reads for DNA samples in the Pt-GG study
Transfection
Experiment
L8L15R1
L8L15R2
L8L15R3
L8L15R4
L8L15R5
L8L15R6
L8L15R7
L8L15R8
L8L15R9
L8L15R10
L8L15R11
L8L15R12
L8L15R13
L8L15R14
L8L15R15
L8L15R16
L8L15R17
L8L15R18
L8L15R19
L8L15R20
L8L15R21
L8L15R22
L8L15R23
L8L15R24

Total
Reads
36024
36207
35457
40351
40306
41563
46500
44003
51500
42392
55695
53285
54559
53104
48927
55594
58006
60290
51834
64230
63154
46743
51651
57671

Reads of
Control
Plasmids
17863
18928
19361
20797
19659
23831
26165
25446
28085
28024
30419
30590
29274
30179
29555
32009
34832
39704
26436
44079
42904
29133
25681
34374

Reads of
Lesion
Plasmids
18161
17279
16096
19554
20647
17732
20335
18557
23415
14368
25276
22695
25285
22925
19372
23585
23174
20586
25398
20151
20250
17610
25970
23297

Transfection
Experiment
L9L16R1
L9L16R2
L9L16R3
L9L16R4
L9L16R5
L9L16R6
L9L16R7
L9L16R8
L9L16R9
L9L16R10
L9L16R11
L9L16R12
L9L16R13
L9L16R14
L9L16R15
L9L16R16
L9L16R17
L9L16R18
L9L16R19
L9L16R20
L9L16R21
L9L16R22
L9L16R23
L9L16R24

Total
Reads
64482
67825
68797
65804
68370
74466
71140
76563
65740
68844
82529
71837
81171
70830
62436
71543
71266
77326
75568
67533
74950
68953
69949
70154

Reads of
Control
Plasmids
37988
37640
39394
37270
37120
44853
41356
46366
36375
40462
49950
39618
47970
40003
35253
43289
41221
47557
43406
40635
41790
40884
37927
39769

Reads of
Lesion
Plasmids
26494
30185
29403
28534
31250
29613
29784
30197
29365
28382
32579
32219
33201
30827
27183
28254
30045
29769
32162
26898
33160
28069
32022
30385

Transfection
Experiment
L10L17R1
L10L17R2
L10L17R3
L10L17R4
L10L17R5
L10L17R6
L10L17R7
L10L17R8
L10L17R9
L10L17R10
L10L17R11
L10L17R12
L10L17R13
L10L17R14
L10L17R15
L10L17R16

Total
Reads
56715
78852
66577
66259
40689
42661
47258
52330
54341
52122
58771
55036
59710
54427
52433
59790

Reads of
Control
Plasmids
41330
55635
38615
39749
19015
20383
17672
21168
21079
20580
25643
24683
27163
22966
23587
26321

Reads of
Lesion
Plasmids
15385
23217
27962
26510
21674
22278
29586
31162
33262
31542
33128
30353
32547
31461
28846
33469

Transfection
Experiment
L11L18R1
L11L18R2
L11L18R3
L11L18R4
L11L18R5
L11L18R6
L11L18R7
L11L18R8
L11L18R9
L11L18R10
L11L18R11
L11L18R12
L11L18R13
L11L18R14
L11L18R15
L11L18R16

Total
Reads
46782
43657
48643
52460
52404
46875
49028
48714
54014
51793
51801
55341
58658
52695
50965
56964

Reads of
Control
Plasmids
34241
30693
35021
37590
37337
29987
32675
32294
36173
33239
33664
38338
38585
33694
33755
38407

Reads of
Lesion
Plasmids
12541
12964
13622
14870
15067
16888
16353
16420
17841
18554
18137
17003
20073
19001
17210
18557
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Total
Reads
53811
57204
57464
50519
58053
52774
41139
39741

Reads of
Control
Plasmids
27940
26774
27886
24620
27008
23931
26785
25207

Reads of
Lesion
Plasmids
25871
30430
29578
25899
31045
28843
14354
14534

Transfection
Experiment
L12L19R1
L12L19R2
L12L19R3
L12L19R4
L12L19R5
L12L19R6
L12L19R7
L12L19R8
L12L19R9
L12L19R10
L12L19R11
L12L19R12
L12L19R13
L12L19R14
L12L19R15
L12L19R16
L12L19R17
L12L19R18
L12L19R19
L12L19R20
L12L19R21
L12L19R22
L12L19R23
L12L19R24

Total
Reads
66628
63410
59615
67930
72946
83461
65460
77384
77126
78838
73492
71107
76450
42905
69864
68766
73579
73856
72559
67281
74570
73241
61487
73060

Reads of
Control
Plasmids
39811
41054
39642
43535
41709
56198
41530
49889
48229
50848
42849
42338
46819
15582
45212
42805
45959
45505
49140
44924
51622
44819
38023
44784

Reads of
Lesion
Plasmids
26817
22356
19973
24395
31237
27263
23930
27495
28897
27990
30643
28769
29631
27323
24652
25961
27620
28351
23419
22357
22948
28422
23464
28276

Transfection
Experiment
L14L21R1
L14L21R2
L14L21R3
L14L21R4
L14L21R5
L14L21R6

Total
Reads
43780
38717
48448
47107
48792
56677

Reads of
Control
Plasmids
19325
20072
19932
21231
22446
25800

Reads of
Lesion
Plasmids
24455
18645
28516
25876
26346
30877

Transfection
Experiment
L10L17R17
L10L17R18
L10L17R19
L10L17R20
L10L17R21
L10L17R22
L10L17R23
L10L17R24

Total
Reads
61006
54630
56546
38641
60615
51836
56257
57467

Reads of
Control
Plasmids
40607
40289
36449
34745
38777
32653
35966
38795

Reads of
Lesion
Plasmids
20399
14341
20097
3896
21838
19183
20291
18672

Transfection
Experiment
L13L20R1
L13L20R2
L13L20R3
L13L20R4
L13L20R5
L13L20R6
L13L20R7
L13L20R8
L13L20R9
L13L20R10
L13L20R11
L13L20R12
L13L20R13
L13L20R14
L13L20R15
L13L20R16
L13L20R17
L13L20R18
L13L20R19
L13L20R20
L13L20R21
L13L20R22
L13L20R23
L13L20R24

Total
Reads
68368
70656
66731
73834
70185
75937
68043
73955
78625
75918
72757
78867
71363
66372
72626
78395
81469
59811
73654
68656
73762
62216
43166
52392

Reads of
Control
Plasmids
46307
45948
40607
46485
44272
45527
43317
49054
51148
49228
46242
52278
40508
41795
47232
51335
49601
38608
47798
45474
46316
37289
19251
21890

Reads of
Lesion
Plasmids
22061
24708
26124
27349
25913
30410
24726
24901
27477
26690
26515
26589
30855
24577
25394
27060
31868
21203
25856
23182
27446
24927
23915
30502

Transfection
Experiment
L23L24R1
L23L24R2
L23L24R3
L23L24R4
L23L24R5
L23L24R6

Total
Reads
62856
55453
65605
64659
51577
76682

Reads of
Control
Plasmids
49312
42078
50502
49128
44095
56799

Reads of
Lesion
Plasmids
13544
13375
15103
15531
7482
19883

Transfection
Experiment
L11L18R17
L11L18R18
L11L18R19
L11L18R20
L11L18R21
L11L18R22
L11L18R23
L11L18R24
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Transfection
Experiment
L14L21R7
L14L21R8
L14L21R9
L14L21R10
L14L21R11
L14L21R12
L14L21R13
L14L21R14
L14L21R15
L14L21R16
L14L21R17
L14L21R18
L14L21R19
L14L21R20
L14L21R21
L14L21R22
L14L21R23
L14L21R24

Total
Reads
51910
50361
50758
52261
52510
54589
57830
45336
50429
54078
46502
48119
46204
41429
45934
41911
42233
44787

Reads of
Control
Plasmids
23832
25094
26100
24623
25159
27700
28064
17483
25363
26037
30175
32340
29511
27453
31675
27266
26767
29171

Reads of
Lesion
Plasmids
28078
25267
24658
27638
27351
26889
29766
27853
25066
28041
16327
15779
16693
13976
14259
14645
15466
15616

Transfection
Experiment
L23L24R7
L23L24R8
L23L24R9
L23L24R10
L23L24R11
L23L24R12
L23L24R13
L23L24R14
L23L24R15
L23L24R16
L23L24R17
L23L24R18
L23L24R19
L23L24R20
L23L24R21
L23L24R22
L23L24R23
L23L24R24

Total
Reads
70990
68275
69109
62660
64814
69844
35231
16229
32519
70670
71456
71659
45740
30318
35904
49326
31946
44769

Reads of
Control
Plasmids
56094
52921
52149
45472
47544
51431
29816
10119
28990
45932
52494
47168
40544
26105
31754
38090
26151
34364

Reads of
Lesion
Plasmids
14896
15354
16960
17188
17270
18413
5415
6110
3529
24738
18962
24491
5196
4213
4150
11236
5795
10405

Note:
L23/L24R13, L23/L24R14 and L23/L24R15 are no DNA negative PCR controls
whereby no DNA was added in PCR reactions.
L23R16, L23R17 and L23R18 are positive control PCR reactions whereby intact and
fully double stranded control plasmids were added in PCR reactions to determine
experimental errors. Similarly, L24R16, L24R17 and L24R18 are positive control PCR
reactions whereby intact and fully double stranded lesion plasmids (without Pt-GG
crosslinks) were added in PCR reactions.
L23/L24R19, L23/L24R20 and L23/L24R21 are negative control reactions for
transfection where control and lesion gap plasmid mixtures were added and incubated
with MEF cells without using transfection reagent.
Similarly, L23/L24R22, L23/L24R23, L23/L24R24 are negative control reactions for
transfection where control and lesion gap plasmid mixtures were added and incubated
with BL2 cells without using transfection reagent.
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Appendix J

Cell lines used for transfection experiments in
the Pt-GG study
Cell line

Transfection experiments

MEF POLI(+/+)

L8L15R1 to L8L15R9

MEF POLI(-/-)

L8L15R10 to L8L15R18

BL2 POLI(+/+)

L8L15R19 to L8L15R24,
L9L16R1 to L9L16R3

BL2 POLI(-/-)

L9L16R4 to L9L16R12

MEF POLH(+/+)

L9L16R13 to L9L16R21

MEF POLH(-/-)

L9L16R22 to L9L16R24,
L10L17R1 to L10L17R6

MEF POLK(+/+)

L10L17R7 to L10L17R15

MEF POLK(-/-)

L10L17R16 to L10L17R24

MEF REV1(+/+)

L11L18R1 to L11L18R9

MEF REV1(-/-)

L11L18R10 to L11L18R18

MEF POLH(-/-) POLI(-/-)

L11L18R19 to L11L18R24
L12L19R1 to L12L19R3

MEF POLH(-/-) POLI(-/-) POLK(-/-), 2091

L12L19R4 to L12L19R12

MEF POLH(-/-) POLI(-/-) POLK(-/-), 2095

L12L19R13 to L12L19R21

MEF POLK(-/-) POLI(-/-), 2092

L12L19R22 to L12L19R24
L13L20R1 to L13L20R6

MEF REV3L(+/Δ), nickname: 3(+)6

L13L20R7 to L13L20R15

MEF REV3L(-/Δ), nickname: 4(-)5

L13L20R16 to L13L20R24

MEF REV3L(-/Δ), nickname: 4(-)11

L14L21R1 to L14L21R9

MEF REV3L(+/+), P53(-/-), nickname: B2

L14L21R10 to L14L21R18

MEF REV3L(+/+), P53(-/-), nickname: B4-9
MEF REV3L(+/+), P53(-/-), nickname: B4-18

L14L21R19 to L14R21R24
L23L24R1 to L23R24R3
L23L24R4 to L23L24R12
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Appendix K Mutation frequencies of control plasmids and
lesion plasmids in the Pt-GG study for each cell
line

Cell lines

Average mutation frequencies of
control plasmids across from GG
(N=9 samples)
st
The 1 insertion The 2nd insertion
step
step
0.00633582
0.00211604
±0.00060603
±0.00042729
0.00623971
0.00210229
±0.00026943
±0.00033156
0.00672665
0.00211498
±0.00037447
±0.00050253
0.00697197
0.00213745
±0.0004663
±0.0002034
0.00671445
0.00213002
±0.00063946
±0.00023077
0.00659034
0.00223973
±0.00070424
±0.0002914
0.00631168
0.00197384
±0.00053691
±0.00028981
0.00647793
0.00205539
±0.00061005
±0.00054222

MEF
POLI(+/+)
MEF
POLI(-/-)
BL2
POLI(+/+)
BL2
POLI(-/-)
MEF
POLH(+/+)
MEF
POLH(-/-)
MEF
POLK(+/+)
MEF
POLK(-/-)
MEF
0.00669208
POLH(-/-)
±0.00032507
POLI(-/-)
MEF
POLK(-/-)
0.00651591
POLI(-/-),
±0.00044
2092
MEF
POLH(-/-)
0.00665362
POLI(-/-)
±0.00021903
POLK(-/-),
2091
Table continues in the next page …

Average mutation frequencies of
lesion plasmids across from Pt-GG
(N=9 samples)
st
The 1 insertion The 2nd insertion
step
step
0.00797014
0.00325844
±0.00235359
±0.00081405
0.00676418
0.00335374
±0.00178312
±0.00046932
0.00357752
0.00274966
±0.00104655
±0.0008659
0.00453663
0.00373258
±0.00094203
±0.00065256
0.01264681
0.00498744
±0.00534483
±0.00091888
0.00967711
0.00426218
±0.00290917
±0.0004818
0.00817649
0.00405642
±0.00205302
±0.00065313
0.00692088
0.00403449
±0.00098325
±0.0004382

0.00218667
±0.00035575

0.00747425
±0.00113811

0.0040025
±0.00033642

0.00215294
±0.00036743

0.00506356
±0.0009081

0.00361153
±0.00053964

0.00221712
±0.00022728

0.00501292
±0.00076192

0.00345792
±0.00056011
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Appendix K continues …
Average mutation frequencies of
control plasmids across from GG
(N=9 samples)
Cell line
st
The 1 insertion The 2nd insertion
step (C1)
step (C2)
MEF
POLH(-/-)
0.00657383
0.00227921
POLI(-/-)
±0.00041924
±0.0005008
POLK(-/-),
2095
MEF
0.00685436
0.00213745
REV1(+/+)
±0.00052085
±0.00030857
MEF
0.00652176
0.00214813
REV1(-/-)
±0.00024146
±0.00035795
MEF
0.00658979
0.00206947
REV3L(+/Δ),
±0.00043858
±0.00023479
3(+)6
MEF
0.00678478
0.00217725
REV3L(-/Δ),
±0.00053557
±0.00046891
4(-)5
MEF
0.00678595
0.0020206
REV3L(-/Δ),
±0.00036631
±0.00028687
4(-)11
MEF
REV3L(+/+)
0.00659605
0.00205079
P53(-/-),
±0.00034117
±0.00025514
B2
MEF
REV3L(+/+)
0.00665444
0.00217355
P53(-/-),
±0.0050896
±0.00023279
B4-9
MEF
REV3L(+/+)
0.00656054
0.00227396
P53(-/-),
±0.00034216
±0.00027169
B4-18

Average mutation frequencies of
lesion plasmids across from Pt-GG
(N=9 samples)
st
The 1 insertion The 2nd insertion
step (C1)
step (C2)
0.00409557
±0.00071602

0.00307922
±0.00065915

0.00756895
±0.00153204
0.00435796
±0.00056597

0.00431359
±0.00063232
0.00338934
±0.0007335

0.01030133
±0.00235666

0.00440965
±0.00076919

0.00490431
±0.00095976

0.00389058
±0.00105612

0.00413251
±0.00091898

0.00370398
±0.00064044

0.00651752
±0.00073177

0.00400263
±0.00060623

0.00498804
±0.00057864

0.00395544
±0.00076486

0.00457931
±0.00109652

0.00427594
±0.00105971
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